Publications and communications of Frédéric Baron

Jorssen, J.* , Van Hulst, G.* , Mollers, K., Pujol, J., Petrellis, G., Baptista, A. P., Schetters, S., Baron, F., Caers, J., Lambrecht, B. N., Dewals, B. G., Bureau, F.* , & Desmet, C.*. (2024). Single-cell proteomics and transcriptomics capture eosinophil development and identify the role of IL-5 in their lineage transit amplification. Immunity. doi:10.1016/j.immuni.2024.04.027
* These authors have contributed equally to this work.

Noronha, N., Durette, C., Cahuzac, M., E Silva, B., Courtois, J., Humeau, J., Sauvat, A., Hardy, M.-P., Vincent, K., Laverdure, J.-P., Lanoix, J., Baron, F., Thibault, P., Perreault, C., & Ehx, G. (2024). Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia. Leukemia. doi:10.1038/s41375-024-02250-6

Baron, F., Efficace, F., Cannella, L., Stevens-Kroef, M., Amadori, S., de Witte, T., Lübbert, M., Venditti, A., & Suciu, S. (March 2024). Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial. American Journal of Hematology, 99 (3), 486 - 489. doi:10.1002/ajh.27196

Bayoudh, F., Giot, J.-B., Descy, J., Fontaine, C., Hayette, M.-P., Baron, F., WILLEMS, E., Beguin, Y., FRIPPIAT, F., & Servais, S. (March 2024). Oral minocycline as systemic therapy for uncomplicated venous access device-related bloodstream infection with coagulase-negative staphylococci after allogeneic hematopoietic cell transplantation. Current Research in Translational Medicine, 72 (1), 103422. doi:10.1016/j.retram.2023.103422

Sparano, F., Giesinger, J. M., Gaidano, G., Anota, A., Cavo, M., Brini, A., Voso, M. T., Venditti, A., Perrone, F., Di Maio, M., Luppi, M., Baron, F., Platzbecker, U., Fazi, P., Vignetti, M., & Efficace, F. (March 2024). Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care System. JCO Oncology Practice, 20 (3), 438 - 447. doi:10.1200/OP.23.00434

Jassin, M., Chloé Onkelinx, E Silva, B., Bocuzzi, V., Marcion, G., Ehx, G., Baron, F., Di Valentin, E., Caers, J., & Nguyen, T. T. (15 February 2024). CAR-T and nanoCAR-T for multiple myeloma: Does smaller mean smarter ? [Poster presentation]. EBMT - EHA 6th European CAR T-cell Meeting, Valence, Spain.

Faville, C.* , E Silva, B.* , Jassin, M., DUBOIS, S., Daulne, C., Cobraiville, G., De Voeght, A., Baron, F., Fillet, M.* , & Ehx, G.*. (06 February 2024). Discovery And Targeting of Persister-specific Antigens in Acute Myeloid Leukemia [Poster presentation]. Télévie Seminar.
* These authors have contributed equally to this work.

Faville, C.* , E Silva, B.* , Jassin, M., DUBOIS, S., Daulne, C., Cobraiville, G., De Voeght, A., Baron, F., Fillet, M.* , & Ehx, G.*. (06 February 2024). Discovery And Targeting of Persister-specific Antigens in Acute Myeloid Leukemia [Paper presentation]. Télévie Seminar.
* These authors have contributed equally to this work.

Jassin, M., Chloé Onkelinx, E Silva, B., Bocuzzi, V., Marcion, G., Ehx, G., Baron, F., Di Valentin, E., Caers, J., & Nguyen, T. T. (06 February 2024). CAR-T and nanoCAR-T for multiple myeloma: Does smaller mean smarter ? [Poster presentation]. Séminaire Télévie 2024.

Kwan, O., Canti, L., Ehx, G., Beguin, Y., & Baron, F. (06 February 2024). Systems vaccinology study of responses to BNT162b2 vaccine in allogeneic hematopoietic stem cell transplant recipients [Poster presentation]. Séminaire des chercheurs Télévie 2024, Bruxelles, Belgium.

Baron, F., Nagler, A., Galimard, J.-E., Sanz, J., Versluis, J., Forcade, E., Chevallier, P., Sirvent, A., Anthias, C., Kuball, J., Furst, S., Rambaldi, A., Sierra, J., von dem Borne, P. A., Gallego Hernanz, M. P., Cluzeau, T., Robinson, S., Raiola, A. M., Labussière-Wallet, H., ... Ciceri, F. (January 2024). Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study. British Journal of Haematology, 204 (1), 250-259. doi:10.1111/bjh.19130

Abou Dalle, I., Labopin, M., Khvedelidze, I., Baron, F., Brissot, E., Bug, G., Esteve, J., Giebel, S., Gorin, N. C., Lanza, F., Nagler, A., Peric, Z., Piemontese, S., Ruggeri, A., Sanz, J., Savani, B. N., Schmid, C., Shouval, R., Spyridonidis, A., ... Mohty, M. (28 November 2023). Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party. Blood, 142 (Supplement 1), 7089-7089. doi:10.1182/blood-2023-187095

Baron, F., Labopin, M., Versluis, J., Vydra, J., Von Dem Borne, P. A., Nicholson, E., Blaise, D., Robinson, S., Kulagin, A., Bulabois, C.-É., Rovira, M., Chevallier, P., Forcade, É., Byrne, J. L., Caballer, J. S., Ruggeri, A., Mohty, M., & Ciceri, F. (28 November 2023). Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT. Blood, 142 (Supplement 1), 2233-2233. doi:10.1182/blood-2023-186293

Bazarbachi, A., Galimard, J.-E., Labopin, M., Abou Dalle, I., Sanz, J., Huang, H., Mayer, J., Solano, C., Simand, C., Griskevicius, L., Maertens, J., Itäla-remes, M., Kaare, A., Gallego Hernanz, M. P., Bug, G., Ribera, J.-M., Gadisseur, A., Schmidt, C., Kwon, M., ... Mohty, M. (28 November 2023). Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party. Blood, 142 (Supplement 1), 657-657. doi:10.1182/blood-2023-182823

Chiusolo, P., Labopin, M., Khvedelidze, I., Baron, F., Brissot, E., Bazarbachi, A., Bug, G., Esteve, J., Giebel, S., Gorin, N. C., Peric, Z., Lanza, F., Nagler, A., Piemontese, S., Ruggeri, A., Sanz, J., Savani, B. N., Schmidt, C., Shouval, R., ... Ciceri, F. (28 November 2023). CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice. Blood, 142 (Supplement 1), 7049-7049. doi:10.1182/blood-2023-182831

Efficace, F., Cannella, L., Thomas, X., Yuksel, M. K., Trisolini, S. M., Saveria, C., Brini, A., Audisio, E., Maurillo, L., Lemoli, R. M., Imovilli, A., Panovska Stavridis, I., Quattrone, M., Ciccone, M., Filardi, N., Fracchiolla, N., Vallisa, D., Crugnola, M., Melillo, L. M. A., ... Baron, F. (28 November 2023). Lifestyle Behaviors and Health-Related Quality of Life in Long-Term Survivors of Acute Myeloid Leukemia: An International Survivorship Study By the Gimema, EORTC Quality of Life and Leukemia Groups. Blood, 142 (Supplement 1), 3801. doi:10.1182/blood-2023-179248

Beguin, C., Kwan, O., Ritacco, C., Debray, J.-C., Dejardin, E., Dubois, S., Köse, M. C., Canti, L., Courtois, J., Seidel, L., Daulne, C., Caers, J., Beguin, Y., Ehx, G., & Baron, F. (17 November 2023). TNF-α priming of human regulatory T cells does not increase their ability to prevent xenogeneic graft-versus-host disease [Paper presentation]. Congrès annuel de la Société Francophone de Greffe de Moelle et Thérapie Cellulaire, Lille, France.

Kwan, O., Canti, L., Ehx, G., Beguin, Y., Humblet-Baron, S., & Baron, F. (16 November 2023). Utilisation de techniques de biologie des systèmes pour une analyse détaillée de la réponse immunitaire au vaccin à ARN messager BNT162b2 chez les patients ayant bénéficié d'une allogreffe [Paper presentation]. 26ème Congrès Annuel de l'Association Française de Cytométrie 2023, Toulouse, France.

Lübbert, M., Wijermans, P. W., Kicinski, M., Chantepie, S., Van der Velden, W. J. F. M., Noppeney, R., Griškevičius, L., Neubauer, A., Crysandt, M., Vrhovac, R., Luppi, M., Fuhrmann, S., Audisio, E., Candoni, A., Legrand, O., Foà, R., Gaidano, G., van Lammeren-Venema, D., Posthuma, E. F. M., ... EORTC Leukemia Group, G. A. G. M. S. G. (November 2023). 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. The Lancet Haematology, 10 (11), 879 - e889. doi:10.1016/S2352-3026(23)00273-9

Voisot, A., Triffaux, F., Roland, I., Meex, C., Detrembleur, N., Baron, F., WILLEMS, E., WALTREGNY, D., Beguin, Y., & Servais, S. (22 September 2023). Endovesical instillation of Cidofovir in the treatment of BK polyomavirus hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Current Research in Translational Medicine, 71 (1), 103366. doi:10.1016/j.retram.2022.103366

E Silva, B., Faville, C., Jassin, M., DUBOIS, S., De Voeght, A., Baron, F., & Ehx, G. (09 September 2023). Characterizing the immune recognition of chemo-persister blasts in acute myeloid leukemia [Poster presentation]. GIGA Day 2023.

Kwan, O., Canti, L., Ehx, G., Humblet-Baron, S., & Baron, F. (04 September 2023). Systems vaccinology study of responses to BNT162b2 vaccine in allogeneic hematopoietic stem cell transplant recipients [Poster presentation]. GIGA Day 2023, Liège, Belgium.

Efficace, F., Al Essa, W., Platzbecker, U., Niscola, P., Palumbo, G. A., Caocci, G., Cottone, F., Breccia, M., Luppi, M., Stauder, R., Ricco, A., Petranovic, D., Baron, F., Voso, M. T., Fianchi, L., Frairia, C., Capodanno, I., Sarlo, C., Fedele, M., ... Vignetti, M. (September 2023). Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA. HemaSphere, 7 (9), 944. doi:10.1097/HS9.0000000000000944

Baron, F., Ruggeri, A., Peczynski, C., Labopin, M., Bourhis, J.-H., Michallet, M., Chevallier, P., Sanz, J., Forcade, E., Saccardi, R., Potter, V., Gluckman, E., Nagler, A., & Mohty, M. (August 2023). Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 58 (8), 936 - 941. doi:10.1038/s41409-023-02000-9

Lambert, N., El Moussaoui, M., Baron, F., Maquet, P., & Darcis, G. (06 July 2023). Virus-Specific T-Cell Therapy for Viral Infections of the Central Nervous System: A Review. Viruses, 15 (7), 1510. doi:10.3390/v15071510

Mohty, M., Malard, F., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Brissot, E., Ciceri, F., Corbacioglu, S., Dalle, J.-H., Dignan, F., Huynh, A., Kenyon, M., Nagler, A., Pagliuca, A., Perić, Z., ... Carreras, E. (July 2023). Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). Bone Marrow Transplantation, 58 (7), 749 - 754. doi:10.1038/s41409-023-01992-8

Burniat, A., Noël, A., Colige, A., Vanderplasschen, A., de Kerchove d'Exaerde, A., Kupper Cardozo, A., Van Keymeulen, A., Moens, A., Bondue, A., Herpain, A., Marchant, A., Loumaye, A., Beck, B., Van den Heyden, B., Corvilain, B., Lakaye, B., Rogister, B., Malgrange, B., Michiels, C., ... Brunko, E. (2023). Cent scientifiques répliquent à SEA (Suppression des Expériences sur l’Animal vivant) et dénoncent sa désinformation. La Libre Belgique.

Ritacco, C., Köse, M. C., Courtois, J., Canti, L., Beguin, C., DUBOIS, S., Vandenhove, B., Servais, S., Caers, J., Beguin, Y., Ehx, G.* , & Baron, F.*. (17 March 2023). Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells. iScience, 26 (3), 106085. doi:10.1016/j.isci.2023.106085
* These authors have contributed equally to this work.

Baron, F., Labopin, M., Tischer, J., Raiola, A. M., Vydra, J., Blaise, D., Chiusolo, P., Stölzel, F., Fanin, R., Chevallier, P., Nagler, A., Ciceri, F., & Mohty, M. (13 February 2023). GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT. Journal of Hematology and Oncology, 16 (1), 10. doi:10.1186/s13045-023-01403-x

Maertens, J., Lodewyck, T., Peter Donnelly, J., Chantepie, S., Robin, C., Blijlevens, N., Turlure, P., Selleslag, D., Baron, F., Aoun, M., Heinz, W. J., Bertz, H., Ráčil, Z., Vandercam, B., Drgona, L., Coiteux, V., Llorente, C. C., Schaefer-Prokop, C., Paesmans, M., ... Acute Leukemia Group of the European Organization for Research and Treatment of. (2023). Empiric versus pre-emptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: a randomized trial of the European organization for Research and Treatment of cancer (EORTC 65091). Clinical Infectious Diseases, 76 (4), 674-682. doi:10.1093/cid/ciac623

Servais, S., Baron, F., LECHANTEUR, C., Seidel, L., BAUDOUX, E., BRIQUET, A., Selleslag, D., Maertens, J., Poire, X., Schroyens, W., Graux, C., De Becker, A., Zachee, P., Ory, A., Herman, J., Kerre, T., & Beguin, Y. (2023). Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis. Frontiers in Immunology, 14. doi:10.3389/fimmu.2023.1106464

Noronha, N., Durette, C., E Silva, B., Courtois, J., Humeau, J., Sauvat, A., Hardy, M.-P., Vincent, K., Laverdure, J.-P., Lanoix, J., Baron, F., Thibault, P.* , Perreault, C.* , & Ehx, G.*. (2022). Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/298893. doi:10.1101/2022.12.02.518683
* These authors have contributed equally to this work.

Efficace, F., Cannella, L., Sparano, F., Giesinger, J. M., Vignetti, M., Baron, F., Bruera, E., Luppi, M., & Platzbecker, U. (December 2022). Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review. HemaSphere, 6 (12), 802. doi:10.1097/HS9.0000000000000802

Baron, F., Labopin, M., Tischer, J., Ciceri, F., Raiola, A. M., Blaise, D., Sica, S., Vydra, J., Fanin, R., Diez-Martin, J. L., Bulabois, C. E., Stölzel, F., Busca, A., Jindra, P., Koc, Y., Chevallier, P., Forcade, E., Rösler, W., Passweg, J., ... Mohty, M. (November 2022). Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia. Bone Marrow Transplantation, 57 (11), 1657-1663. doi:10.1038/s41409-022-01781-9

Nagler, A., Labopin, M., Cornelissen, J. J., Forcade, E., Chevallier, P., Fegueux, N., Sierra, J., Desmier, D., Labussière-Wallet, H., Byrne, J. L., Loschi, M., Blaise, D., Baron, F., Ruggeri, A., & Mohty, M. (October 2022). Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 57 (10), 1514-1519. doi:10.1038/s41409-022-01742-2

Ruggeri, A., Galimard, J.-E., Labopin, M., Rafii, H., Blaise, D., Ciceri, F., Diez-Martin, J.-L., Cornelissen, J., Chevallier, P., Sanchez-Guijo, F., Nicholson, E., Castagna, L., Forcade, E., Kuball, J., Rovira, M., Koc, Y., Pavlu, J., Gulbas, Z., Vydra, J., ... Mohty, M. (October 2022). Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 28 (10), 710.e1-710.e10. doi:10.1016/j.jtct.2022.07.006

De Voeght, A., WILLEMS, E., Servais, S., Seidel, L., Pirotte, M., Massion, P., Layios, N., Pereira, M., Misset, B., CANIVET, J.-L., Beguin, Y., & Baron, F. (31 August 2022). Overall Survival Rate in Allogeneic Stem Cell Transplanted Patients Requiring Intensive Care Can Be Predicted by the Prognostic Index for Critically Ill Allogeneic Transplantation Patients (PICAT) and the Sequential Organ Failure Assessment (SOFA) Scores. Cancers, 14 (17), 4266. doi:10.3390/cancers14174266

BARON, F., Labopin, M., Tischer, J., Ciceri, F., Raiola, A. M., Blaise, D., Sica, S., Vydra, J., Fanin, R., Stölzel, F., Busca, A., Diez-Martin, J. L., Koc, Y., Nagler, A., & Mohty, M. (August 2022). Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age. American Journal of Hematology, 97 (8), 1065-1074. doi:10.1002/ajh.26627

Ehx, G., Nandita, N., Durette, C., Courtois, J., Hardy, M.-P., Vincent, K., Laverdure, J.-P., Lanoix, J., Baron, F., Thibault, P., & Perreault, C. (June 2022). Proteogenomic characterization of 5-azacytidine effects on acute myeloid leukemia immunopeptidome. HemaSphere, 6, 300-301. doi:10.1097/01.hs9.0000844488.25409.8e

SERVAIS, S., BEGUIN, Y., & BARON, F. (27 May 2022). Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia. Stem Cells Translational Medicine, 11 (5), 461-477. doi:10.1093/stcltm/szac015

Lambert, N., El Moussaoui, M., Ritacco, C., MOISE, M., PAULUS, A., DELVENNE, P., BARON, F., SADZOT, B., & MAQUET, P. (03 May 2022). Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report. Frontiers in Immunology, 13, 889148. doi:10.3389/fimmu.2022.889148

Baron, F., Caers, J., & Humblet-Baron, S. (May 2022). Serological response to SARS-CoV-2 mRNA-LNP vaccine in patients with multiple myeloma: a negative impact of CD38(+) Treg? British Journal of Haematology, 197 (4), 391-393. doi:10.1111/bjh.18110

BARZIN, A., Geurten, C., WILLEMS, E., Baron, F., Beguin, Y., & Servais, S. (May 2022). Maladie du greffon contre l’hôte aiguë et chronique après allogreffe de cellules souches hématopoïétiques. Revue Médicale de Liège, 77 (5-6), 345 - 353.

Canti, L., Ariën, K. K., Desombere, I., Humblet-Baron, S., Pannus, P., Heyndrickx, L., HENRY, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., SEIDEL, L., Michiels, J., Willems, B., Goossens, M. E., Beguin, Y., Marchant, A., & Baron, F. (11 April 2022). Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients. Cancer Cell, 40 (4), 335-337. doi:10.1016/j.ccell.2022.02.005

GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211.

Faville, C., Nix, C., Baron, F., Ehx, G., & Fillet, M. (02 February 2022). Discovery of tumor-specific antigens presented by diapaused acute myeloid leukemia (AML) cells using ion-mobility mass spectrometry [Paper presentation]. CIRM-Day.

Schmid, C., Labopin, M., Schaap, N., Veelken, H., Brecht, A., Stadler, M., Finke, J., Baron, F., Collin, M., Bug, G., Ljungman, P., Blaise, D., Tischer, J., Bloor, A., Kulagin, A., Giebel, S., Gorin, N.-C., Esteve, J., Ciceri, F., ... Mohty, M. (February 2022). Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transplantation, 57, 215 - 223. doi:10.1038/s41409-021-01515-3

Baron, F. (2022). Individualised doses of anti-thymocyte globulin and immune recovery after allogeneic HSCT. The Lancet Haematology, 9 (2), 84-e86. doi:10.1016/S2352-3026(21)00383-5

BARON, F., Canti, L., Ariën, K. K., Kemlin, D., Desombere, I., Gerbaux, M., Pannus, P., BEGUIN, Y., Marchant, A., & Humblet-Baron, S. (2022). Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients. Frontiers in Immunology, 13, 827242. doi:10.3389/fimmu.2022.827242

Poiré, X., Graux, C., ORY, A., Herman, J., Baron, F., Schoemans, H., Lewalle, P., De Becker, A., Deeren, D., Berneman, Z., Kerre, T., Zachée, P., Selleslag, D., & Beguin, Y. (2022). Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS). Bone Marrow Transplantation, 57, 116-118. doi:10.1038/s41409-021-01464-x

Baron, F., Labopin, M., Blaise, D., Itälä-Remes, M., Socié, G., Forcade, E., Yakoub-Agha, I., Gorin, N. C., Esteve, J., Nagler, A., & Mohty, M. (2021). Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 56, 461-469. doi:10.1038/s41409-020-01051-6

Baron, F., Ngoya, M., Labopin, M., Cornelissen, J. J., Ganser, A., Forcade, E., Sengeloev, H., Socié, G., Blaise, D., Bornhäuser, M., Valerius, T., Reinhardt, H. C., Kroger, N., Ruggeri, A., Nagler, A., & Mohty, M. (2021). Comparison of long-term outcome for AML patients alive free of disease two years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 56, 2742-2748. doi:10.1038/s41409-021-01387-7

Bazarbachi, A. H., Al Hamed, R., Labopin, M., Halaburda, K., Labussiere, H., Bernasconi, P., Schroyens, W., Gandemer, V., Schaap, N. P. M., Loschi, M., Jindra, P., Snowden, J., Wu, D., Guffroy, B., Rovira, M., Chantepie, S. P., Poiré, X., Lopez-Corral, L., Nikolousis, M., ... Mohty, M. (2021). Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 56, 917-927. doi:10.1038/s41409-020-01135-3

Brissot, E., Labopin, M., Baron, F., Bazarbachi, A., Bug, G., Ciceri, F., Esteve, J., Giebel, S., Gilleece, M. H., Gorin, N.-C., Lanza, F., Peric, Z., Ruggeri, A., Sanz, J., Savani, B. N., Schmid, C., Shouval, R., Spyridonidis, A., Versluis, J., ... Mohty, M. (2021). Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 56, 532-535. doi:10.1038/s41409-020-0970-x

Canti, L.* , Humblet-Baron, S.* , Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A., & Baron, F. (2021). Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Journal of hematology & oncology, 14 (1), 174. doi:10.1186/s13045-021-01190-3
* These authors have contributed equally to this work.

Courtois, J., Ritacco, C., DUBOIS, S., Canti, L., Vandenhove, B., SEIDEL, L., Daulne, C., CAERS, J., SERVAIS, S., Beguin, Y., Ehx, G., & BARON, F. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 56, 2672-2681. doi:10.1038/s41409-021-01363-1

Cruijsen, M., Hilberink, J. R., van der Velden, W. J. F. M., Jansen, J. H., Bär, B., Schaap, N. P. M., de Haan, A., Mulder, A. B., de Groot, M. R., Baron, F., Vellenga, E., Blijlevens, N. N. M., & Huls, G. (2021). Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 56, 1964-1970. doi:10.1038/s41409-021-01272-3

DE VOEGHT, A., JASPERS, A., BEGUIN, Y., Baron, F., & DE PRIJCK, B. (2021). Principes généraux de la prise en charges des leucémies aiguës de l’adulte en 2021 en Belgique. Revue Médicale de Liège, 76, 470-475.

Delie, A., Verlinden, A., Beel, K., Deeren, D., Mazure, D., Baron, F., Breems, D., De Becker, A., Graux, C., Lewalle, P., Maertens, J., Poire, X., Schoemans, H., Selleslag, D., Van Obbergh, F., & Kerre, T. (2021). Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature. Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine, 76, 500-508. doi:10.1080/17843286.2020.1754635

Dholaria, B., Labopin, M., Sanz, J., Ruggeri, A., Cornelissen, J., Labussière-Wallet, H., Blaise, D., Forcade, E., Chevallier, P., Grassi, A., Zubarovskaya, L., Kuball, J., Ceballos, P., Ciceri, F., Baron, F., Savani, B. N., Nagler, A., & Mohty, M. (2021). Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. Journal of hematology & oncology, 14 (1), 76. doi:10.1186/s13045-021-01086-2

Duray, E., Lejeune, M., Baron, F., Beguin, Y., Devoogdt, N., Krasniqi, A., Lauwers, Y., Zhao, Y. J., D'Huyvetter, M., Dumoulin, M., & Caers, J. (2021). A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. Journal of hematology & oncology, 14 (1), 183. doi:10.1186/s13045-021-01171-6

Ehx, G.* , Ritacco, C.* , HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505
* These authors have contributed equally to this work.

Ingels, J., De Smet, S., Heyns, K., Lootens, N., Segaert, J., Taghon, T., Leclercq, G., Vermaelen, K., WILLEMS, E., BAUDOUX, E., Kerre, T., Baron, F., & Vandekerckhove, B. (2021). Treatment of a patient with severe cytomegalovirus (CMV) infection after haploidentical stem cell transplantation with donor-derived CMV-specific T cells. Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine, 76, 482-486. doi:10.1080/17843286.2020.1752446

Jimenez Jimenez, A. M., De Lima, M., Komanduri, K. V., Wang, T. P., Zhang, M.-J., Chen, K., Abdel-Azim, H., Abid, M. B., Aljurf, M., Alkhateeb, H., Assal, A., Bacher, U., Baron, F., Battiwalla, M., Beitinjaneh, A., Bejanyan, N., Bhatt, V. R., Byrne, M., Cahn, J.-Y., ... Weisdorf, D. (2021). An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplantation, 56, 3068-3077. doi:10.1038/s41409-021-01450-3

Lejeune, M., Duray, E., Peipp, M., Clémenceau, B., Baron, F., Beguin, Y., & Caers, J. (2021). Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma. Cancers, 13 (12), 3072. doi:10.3390/cancers13123072

Nagler, A.* , Baron, F.* , Labopin, M., Polge, E., Esteve, J., Bazarbachi, A., Brissot, E., Bug, G., Ciceri, F., Giebel, S., Gilleece, M. H., Gorin, N.-C., Lanza, F., Peric, Z., Ruggeri, A., Sanz, J., Savani, B. N., Schmid, C., Shouval, R., ... Mohty, M. (2021). Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplantation, 56, 218-224. doi:10.1038/s41409-020-01005-y
* These authors have contributed equally to this work.

Narinx, J., SERVAIS, S., BARON, F., BEGUIN, Y., & WILLEMS, E. (2021). Allogreffes de cellules souches hématopoïétiques : principes généraux et progrès récents. Revue Médicale de Liège, 76, 464-469.

PIROTTE, M., Fillet, M., SEIDEL, L., JASPERS, A., Baron, F., & Beguin, Y. (2021). Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant. American Journal of Hematology, 96 (10), 1275-1286. doi:10.1002/ajh.26300

Ritacco, C.* , Ehx, G.* , GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0
* These authors have contributed equally to this work.

Shouval, R., Fein, J. A., Labopin, M., Cho, C., Bazarbachi, A., Baron, F., Bug, G., Ciceri, F., Corbacioglu, S., Galimard, J.-E., Giebel, S., Gilleece, M. H., Giralt, S., Jakubowski, A., Montoto, S., O'Reilly, R. J., Papadopoulos, E. B., Peric, Z., Ruggeri, A., ... Nagler, A. (2021). Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. The Lancet Haematology, 8 (3), 205-e215. doi:10.1016/S2352-3026(20)30394-X

Vandenhove, B., Canti, L., Schoemans, H., Beguin, Y., Baron, F., Graux, C., Kerre, T., & SERVAIS, S. (21 October 2020). How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation. Frontiers in Immunology, 11, 583564. doi:10.3389/fimmu.2020.583564

Baron, F., Labopin, M., Ruggeri, A., Monacord, C. S. D. M., Sierra, J., Robinson, S., Labussière-Wallet, H., Potter, M., Ribera, J.-M., Deconinck, E., Rambaldi, A., Rohrlich, P.-S., de Revel, T., Gluckman, E., Monacord, C. S. D. M., Nagler, A., & Mohty, M. (September 2020). Impact of detectable measurable residual disease on umbilical cord blood transplantation. American Journal of Hematology, 95 (9), 1057-1065. doi:10.1002/ajh.25879

Hsu, J., Van Besien, K., & Baron, F. (July 2020). Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation? Leukemia and Lymphoma, 61 (7), 1529-1534. doi:10.1080/10428194.2020.1767291

DE VOEGHT, A., CALMES, D., BECK, F., SYLVESTRE, J.-B., DELVENNE, P., PETERS, P., VERTENOEIL, G., BARON, F., LAYIOS, N., & CANIVET, J.-L. (2020). Thrombotic microvascular injury is not mediated by thrombotic microangiopathy despite systemic complement activation in Covid-19 patients. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/256301.

Ritacco, C., Ehx, G., Canti, L., DUBOIS, S., Vandenhove, B., SERVAIS, S., Beguin, Y., & Baron, F. (01 March 2020). Ptcy Prevents Xenogeneic Gvhd without Abrogating Gvl Effects. Biology of Blood and Marrow Transplantation, 26 (3), 168. doi:10.1016/j.bbmt.2019.12.028

Baron, F., Efficace, F., Cannella, L., Muus, P., Trisolini, S., Halkes, C. J. M., Fazi, P., Vignetti, M., Marie, J.-P., Chiusolo, P., van der Velden, W., La Sala, E., Vitolo, U., Thomas, X., Lefrère, F., Di Raimondo, F., Bourhis, J.-H., Specchia, G., Guimarães, J. E., ... Suciu, S. (2020). Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study. American Journal of Hematology, 95 (7), 749-758. doi:10.1002/ajh.25795

Baron, F., Efficace, F., Cannella, L., Willemze, R., Vignetti, M., Muus, P., Marie, J.-P., Ferrero, D., Fazi, P., La Sala, E., Bourhis, J.-H., Fabbiano, F., Bosi, A., Sborgia, M., Martinelli, G., Wittnebel, S., Trisolini, S., Petti, M. C., Halkes, C. J. M., ... Suciu, S. (2020). Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients. Haematologica, 105 (1), 13-e16. doi:10.3324/haematol.2019.221333

Baron, F., Galimard, J.-E., Labopin, M., Yakoub-Agha, I., Niittyvuopio, R., Kroger, N., Griskevicius, L., Wu, D., Forcade, E., Richard, C., Aljurf, M., Helbig, G., Labussiere-Wallet, H., Mohty, M., & Nagler, A. (2020). Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin. Haematologica, 105, 1138-1146. doi:10.3324/haematol.2019.227603

Baron, F., Labopin, M., Savani, B. N., Beohou, E., Niederwieser, D., Eder, M., Potter, V., Kröger, N., Beelen, D., Socié, G., Itälä-Remes, M., Bornhäuser, M., Mohty, M., & Nagler, A. (2020). Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. British Journal of Haematology, 188, 428-437. doi:10.1111/bjh.16185

Baron, F., & Savani, B. N. (2020). Graft-versus-host-disease does not help acute lymphoblastic leukaemia patients with measurable residual disease. British Journal of Haematology, 190 (1), 22-23. doi:10.1111/bjh.16570

Bazarbachi, A., Bug, G., Baron, F., Brissot, E., Ciceri, F., Dalle, I. A., Döhner, H., Esteve, J., Floisand, Y., Giebel, S., Gilleece, M., Gorin, N.-C., Jabbour, E., Aljurf, M., Kantarjian, H., Kharfan-Dabaja, M., Labopin, M., Lanza, F., Malard, F., ... Mohty, M. (2020). Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3internal tandem duplication: A position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 105 (6), 1507-1516. doi:10.3324/haematol.2019.243410

Dholaria, B., Savani, B. N., Labopin, M., Luznik, L., Ruggeri, A., Mielke, S., Al Malki, M. M., Kongtim, P., Fuchs, E., Huang, X.-J., Locatelli, F., Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Ben Soussan, P., Arnault, Y., Handgretinger, R., ... Mohty, M. (2020). Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica, 105 (1), 47-58. doi:10.3324/haematol.2019.219790

Mohty, M., Malard, F., Abecasis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Basak, G., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J.-H., Dignan, F., Fukuda, T., Huynh, A., Kuball, J., ... Carreras, E. (2020). Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplantation, 55, 485-495. doi:10.1038/s41409-019-0705-z

Ramadan, S. M., Suciu, S., Stevens-Kroef, M. J. P. L., Willemze, R., Amadori, S., de Witte, T., Löwenberg, B., Muus, P., Labar, B., Meert, L., de Schaetzen, G., Meloni, G., Leone, G., Vignetti, M., Marie, J.-P., Lübbert, M., & Baron, F. (2020). Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials. Cancers, 12 (11), 3334. doi:10.3390/cancers12113334

Spyridonidis, A., Labopin, M., Savani, B. N., Niittyvuopio, R., Blaise, D., Craddock, C., Socié, G., Platzbecker, U., Beelen, D., Milpied, N., Cornelissen, J. J., Ganser, A., Huynh, A., Griskevicius, L., Giebel, S., Brissot, E., Malard, F., Esteve, J., Peric, Z., ... Mohty, M. (2020). Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplantation, 55, 1114-1125. doi:10.1038/s41409-020-0803-y

Vandenhove, B.* , Canti, L.* , Schoemans, H., BEGUIN, Y., BARON, F., WILLEMS, E., Graux, C., Kerre, T.* , & SERVAIS, S.*. (2020). Acute graft-versus-host disease: diagnosis, pathophysiology and prevention. Belgian Journal of Hematology, 11 (4), 159-173.
* These authors have contributed equally to this work.

Baron, F., Labopin, M., Ruggeri, A., Ehninger, G., Bonifazi, F., Stelljes, M., Sanz, J., Stuhler, G., Bosi, A., Kroger, N., Van Lint, M. T., Ganser, A., Forcade, E., Mohty, M., Gluckman, E., & Nagler, A. (2019). Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. Blood Cancer Journal, 9 (4), 46. doi:10.1038/s41408-019-0204-x

Baron, F., Labopin, M., Ruggeri, A., Volt, F., Mohty, M., Blaise, D., Chevallier, P., Sanz, J., Fegueux, N., Cornelissen, J. J., Rambaldi, A., Savani, B., Gluckman, E., & Nagler, A. (2019). Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukemia in first remission. Journal of Internal Medicine, 285 (4), 446-454. doi:10.1111/joim.12870

BARON, F., Stevens-Kroef, M., Kicinski, M., Meloni, G., Muus, P., Marie, J.-P., Halkes, C. J. M., Thomas, X., Vrhovac, R., Albano, F., Lefrere, F., Sica, S., Mancini, M., Venditti, A., Hagemeijer, A., Jansen, J. H., Amadori, S., de Witte, T., Willemze, R., & Suciu, S. (2019). Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. Haematologica, 104, 1168-1175. doi:10.3324/haematol.2018.204826

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007

ERPICUM, P., WEEKERS, L., DETRY, O., BONVOISIN, C., DELBOUILLE, M.-H., GREGOIRE, C., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., MAGGIPINTO, G., SOMJA, J., Pottel, H., Baron, F., Jouret, F., & BEGUIN, Y. (2019). Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study. Kidney International, 95, 693-707. doi:10.1016/j.kint.2018.08.046

Giebel, S., Boumendil, A., Labopin, M., Seesaghur, A., Baron, F., Ciceri, F., Esteve, J., Gorin, N.-C., Savani, B., Schmid, C., Wetten, S., Mohty, M., & Nagler, A. (2019). Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Annals of Hematology, 98 (10), 2389-2398. doi:10.1007/s00277-019-03771-2

Giebel, S., Marks, D. I., Boissel, N., Baron, F., Chiaretti, S., Ciceri, F., Cornelissen, J. J., Doubek, M., Esteve, J., Fielding, A., Foa, R., Gorin, N.-C., Gokbuget, N., Hallbook, H., Hoelzer, D., Paravichnikova, E., Ribera, J.-M., Savani, B., Rijneveld, A. W., ... Dombret, H. (2019). Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 54, 798-809. doi:10.1038/s41409-018-0373-4

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619

Lee, C. J., Savani, B. N., Mohty, M., Gorin, N. C., Labopin, M., Ruggeri, A., Schmid, C., Baron, F., Esteve, J., Giebel, S., Ciceri, F., & Nagler, A. (2019). Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 54, 519-530. doi:10.1038/s41409-018-0286-2

Monaco, F., Scott, B. L., Chauncey, T. R., Petersen, F. B., Storer, B. E., Baron, F., Flowers, M. E., Deeg, H. J., Maloney, D. G., Storb, R., & Sandmaier, B. M. (2019). Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms. Haematologica, 104 (6), 1221-1229. doi:10.3324/haematol.2018.199398

Ofran, Y., Beohou, E., Labopin, M., Blaise, D., Cornelissen, J. J., de Groot, M. R., Socié, G., Huynh, A., Maertens, J., Baron, F., Mohty, M., & Nagler, A. (2019). Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 184, 643-646. doi:10.1111/bjh.15131

Ruggeri, A., Labopin, M., Savani, B., Paviglianiti, A., Blaise, D., Volt, F., Ciceri, F., Bacigalupo, A., Tischer, J., Chevallier, P., Koc, Y., Cornelissen, J. J., Ehninger, G., Sanz, G., Deconinck, E., Rocha, V., Baron, F., Mohty, M., Gluckman, E., & Nagler, A. (2019). Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. Bone Marrow Transplantation, 54, 1987-1994. doi:10.1038/s41409-019-0582-5

Schmid, C., Labopin, M., Schaap, N., Veelken, H., Schleuning, M., Stadler, M., Finke, J., Hurst, E., BARON, F., Ringden, O., Bug, G., Blaise, D., Tischer, J., Bloor, A., Esteve, J., Giebel, S., Savani, B., Gorin, N.-C., Ciceri, F., ... Nagler, A. (2019). Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. British Journal of Haematology, 184, 782-787. doi:10.1111/bjh.15691

WITHOFS, N., Beguin, Y., COUSIN, F., Tancredi, T., SIMONI, P., Alvarez-Miezentseva, V., DE PRIJCK, B., HAFRAOUI, K., Bonnet, C., Baron, F., Hustinx, R., & Caers, J. (2019). Dual-tracer PET/CT scan after injection of combined [ 18 F]NaF and [ 18 F]FDG outperforms MRI in the detection of myeloma lesions. Hematological Oncology, 37, 193-201. doi:10.1002/hon.2600

Farhat, K., Bodart, G., Charlet-Renard, J. D. C., Desmet, C., Moutschen, M., Beguin, Y., Baron, F., Melin, P., Quatresooz, P., Parent, A.-S., Desmecht, D., Sirard, J.-C., Salvatori, R., Martens, H., & Geenen, V. (02 October 2018). Growth hormone (GH) deficient mice with GHRH ablation are severely deficient in vaccine and immune responses against Streptococcus pneumoniae. Frontiers in Immunology, 9, 2175. doi:10.3389/fimmu.2018.02175

Colonval, M., Iovino, M., Esser, N., Dehairs, J., Ehx, G., Baron, F., Piette, J., Swinnen, J., Paquot, N., & Legrand, S. (26 June 2018). Obesity induces metabolic and phenotypic variations in blood monocytes and NK cells [Poster presentation]. Cell Symposia: Translational Immunometabolism.

Bakker, J., Balthazart, J., Baron, F., Beguin, Y., Bettendorff, L., Blanpain, C., Bureau, F., Caers, J., Cani, P., Cataldo, D., Cornil, C., Clercx, C., Cloots, R., Colige, A., Daube, G., De Backer, O., de Kerchove d'Exaerde, A., Desmecht, D., Desmet, C., ... Wittamer, V. (2018). La souris, le patient, et le faux expert. Décryptage d'une mystification. Le Vif. L'Express.

Farhat, K., Bodart, G., Desmet, C., Moutschen, M., Beguin, Y., Baron, F., Salvatori, R., Martens, H., & Geenen, V. (20 March 2018). GHRH-deleted Mice Are Severely Deficient in Vaccine And Immunological Responses Against Streptococcus Pneumoniae [Paper presentation]. ENDO 2018, Chicago, United States.

Baron, F., Labopin, M., Ruggeri, A., Cornelissen, J. J., Meijer, E., Sengeloev, H., Niederwieser, D., De Groot, M. R., Schouten, H. C., Milpied, N., Blaise, D., Savani, B. N., Gluckman, E., Mohty, M., & Nagler, A. (2018). Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. Clinical Cancer Research, 24, 2794-2803. doi:10.1158/1078-0432.CCR-17-3622

Baron, F., Ruggeri, A., Beohou, E., Labopin, M., Mohty, M., Sanz, J., Vigouroux, S., Furst, S., Bosi, A., Chevallier, P., Cornelissen, J. J., Michallet, M., Sierra, J., Karakasis, D., Savani, B. N., Gluckman, E., & Nagler, A. (2018). Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. Journal of Internal Medicine, 283, 178-189. doi:10.1111/joim.12696

Baron, F., Stevens-Kroef, M., Kicinski, M., Meloni, G., Muus, P., Marie, J.-P., Halkes, C. J. M., Thomas, X., Vrhovac, R., Specchia, G., Lefrere, F. S., Sica, S., Mancini, M., Venditti, A., Hagemeijer, A., Becker, H., Jansen, J. H., Amadori, S., de Witte, T., ... Suciu, S. (2018). Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. Annals of Hematology, 97, 1785-1795. doi:10.1007/s00277-018-3396-4

Devillier, R., Labopin, M., Chevallier, P., Ledoux, M.-P., Socie, G., Huynh, A., Bourhis, J.-H., Cahn, J.-Y., Roth-Guepin, G., Mufti, G., Desmier, D., Michallet, M., Fegueux, N., Ciceri, F., Baron, F., Blaise, D., Nagler, A., & Mohty, M. (2018). Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. Bone Marrow Transplantation, 53, 431-437. doi:10.1038/s41409-017-0043-y

Dupont, L., Ehx, G., Chantry, M., Monseur, C., Leduc, C., Janssen, L., Cataldo, D., Thiry, M., Jérôme, C., Thomassin, J.-M., Nusgens, B., Dubail, J., Baron, F., & Colige, A. (2018). Spontaneous atopic dermatitis due to immune dysregulation in mice lacking Adamts2 and 14. Matrix Biology, 70, 140-157. doi:10.1016/j.matbio.2018.04.002

Ehx, G., SOMJA, J., Warnatz, H.-J., Ritacco, C., HANNON, M., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Lehrach, H., Belle, L., Humblet-Baron, S., & BARON, F. (2018). Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2/HHD mice. Frontiers in Immunology, 9, 1943. doi:10.3389/fimmu.2018.01943

Giannotti, F., Labopin, M., Shouval, R., Sanz, J., Arcese, W., Angelucci, E., Sierra, J., Santasusana, J.-M. R., Santarone, S., Benedetto, B., Rambaldi, A., Saccardi, R., Blaise, D., Carella, M. A., Rocha, V., Baron, F., Mohty, M., Ruggeri, A., & Nagler, A. (2018). Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: An EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. Journal of Hematology and Oncology, 11 (1), 110. doi:10.1186/s13045-018-0655-8

Heusschen, R., Muller, J., Duray, E., WITHOFS, N., Bolomsky, A., Baron, F., Beguin, Y., Menu, E., Ludwig, H., & Caers, J. (2018). Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Leukemia and Lymphoma, 59, 14-28. doi:10.1080/10428194.2017.1323272

Muller, J., Bolomsky, A., Dubois, S., Duray, E., Stangelberger, K., Plougonven, E., Lejeune, M., Léonard, A., Marty, C., Hempel, U., Baron, F., BEGUIN, Y., Cohen-Solal, M., Ludwig, H., Heusschen, R., & CAERS, J. (2018). Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease. Haematologica, 103, 1359-1368. doi:10.3324/haematol.2017.185397

Pirotte, M.* , Forte, F.* , Lutteri, L., WILLEMS, E., DURAN, U., Belle, L., Baron, F., BEGUIN, Y., Maquet, P., BODART, O.* , & Servais, S.*. (2018). Neuronal surface antibody-mediated encephalopathy as manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Journal of Neuroimmunology, 323, 115-118. doi:10.1016/j.jneuroim.2018.08.003
* These authors have contributed equally to this work.

Schoemans, H. M., Goris, K., Van Durm, R., Fieuws, S., De Geest, S., Pavletic, S. Z., Im, A., Wolff, D., Lee, S. J., Greinix, H., Duarte, R. F., Poire, X., Selleslag, D., Lewalle, P., Kerre, T., Graux, C., Baron, F., Maertens, J. A., & Dobbels, F. (2018). The eGVHD App has the potential to improve the accuracy of graft versus host disease assessment: a multicenter randomized controlled trial. Haematologica, 103, 1698-1707. doi:10.3324/haematol.2018.190777

Sengsayadeth, S., Gatwood, K. S., Boumendil, A., Labopin, M., Finke, J., Ganser, A., Stelljes, M., Ehninger, G., Beelen, D., Niederwieser, D., Blaise, D., Dreger, P., Mufti, G., Chevallier, P., Mailhol, A., Gilleece, M. H., Gorin, N., Esteve, J., Ciceri, F., ... Nagler, A. (2018). Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. Blood Advances, 2 (16), 2127-2135. doi:10.1182/bloodadvances.2018019976

Sengsayadeth, S., Labopin, M., Boumendil, A., Finke, J., Ganser, A., Stelljes, M., Ehninger, G., Beelen, D., Niederwieser, D., Blaise, D., Dreger, P., Mufti, G., Chevallier, P., Mailhol, A., Gatwood, K. S., Gorin, N., Esteve, J., Ciceri, F., Baron, F., ... Nagler, A. (2018). Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biology of Blood and Marrow Transplantation. doi:10.1016/j.bbmt.2018.04.008

Servais, S., Baron, F., LECHANTEUR, C., SEIDEL, L., Selleslag, D., Maertens, J., BAUDOUX, E., Zachee, P., Van Gelder, M., Noens, L., Kerre, T., Lewalle, P., Schroyens, W., ORY, A., & Beguin, Y. (2018). Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graftversus- host disease: A multicenter prospective study. Oncotarget, 9 (29), 20590-20604. doi:10.18632/oncotarget.25020

Thanarajasingam, G., Minasian, L. M., Baron, F., Cavalli, F., De Claro, R. A., Dueck, A. C., El-Galaly, T. C., Everest, N., Geissler, J., Gisselbrecht, C., Gribben, J., Horowitz, M., Ivy, S. P., Jacobson, C. A., Keating, A., Kluetz, P. G., Krauss, A., Kwong, Y. L., Little, R. F., ... Habermann, T. M. (2018). Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. The Lancet Haematology, 5, 563-598. doi:10.1016/S2352-3026(18)30051-6

Vrancken, L., Muller, J., Lejeune, M., Grégoire, C., Delens, L., Jaspers, A., Servais, S., DE PRIJCK, B., Baron, F., Caers, J., & Beguin, Y. (2018). Nouveautes dans la prise en charge du myelome. Revue Médicale Suisse, 14 (615), 1438-1442.

Amorim, C., Andris, F., Arckens, L., Arnould, T., Aron, S., Bakker, J., Balligand, M., Balthazart, J., Baron, F., Beck, B., Beguin, Y., Behets, C., Bellefroid, E., Bertrand, L., Bettendorff, L., Bindels, L., Blankert, B., Blanpain, C., Bondue, A., ... Wittamer, V. (2017). L’expérimentation animale reste indispensable (OPINION). La Libre Belgique.

Humblet-Baron, S., Schönefeldt, S., Garcia-Perez, J. E., Baron, F., Pasciuto, E., & Liston, A. (November 2017). Cytotoxic T-lymphocyte-associated protein 4-Ig effectively controls immune activation and inflammatory disease in a novel murine model of leaky severe combined immunodeficiency. Journal of Allergy and Clinical Immunology, 140 (5), 1394-1403.e8. doi:10.1016/j.jaci.2016.12.968

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., Briquet, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & Beguin, Y. (July 2017). Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study. Journal of Hepatology, 67 (1), 47-55. doi:10.1016/j.jhep.2017.03.001

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, F., & BARON, F. (24 May 2017). Th17 cells impact on xenogeneic graft-versus-host disease [Poster presentation]. 2017 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

Farhat, K., Bodart, G., RENARD, J. D. C., Desmet, C., MOUTSCHEN, M., Beguin, Y., Baron, F., Salvatori, R., Geenen, V., & Martens, H. (23 May 2017). A surprising and dramatic neuroendocrine-immune phenotype of mice deficient in Growth Hormone-Releasing Hormone (GHRH) [Poster presentation]. European Congress of Endocrinology, Lisbonne, Portugal. doi:10.1530/endoabs.49.EP883

Farhat, K., Bodart, G., Renard, C., Desmet, C., MOUTSCHEN, M., BARON, F., Beguin, Y., Salvatori, R., Martens, H., & GEENEN, V. (May 2017). A surprising and dramatic neuroendocrine-immune phenotype of mice deficient in Growth Hormone-Releasing Hormone (GHRH) [Poster presentation]. The 19th European Congress of Endocrinology, Lisbon, Portugal.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., Beguin, Y., & Baron, F. (27 March 2017). Xenogeneic graft-versus-host disease : Impact of Th17 cells [Poster presentation]. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France.

Ehx, G., Hannon, M., DUBOIS, S., Daulne, C., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (March 2017). Immunomodulatory effects of rapamycin in xenogeneic Graft versus Host Disease. Biology of Blood and Marrow Transplantation, 23 (3), 365–S366. doi:10.1016/j.bbmt.2016.12.314

Ehx, G., HANNON, M., Dubois, S., Daulne, C., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (10 February 2017). Immunomodulatory effects of rapamycin in xenogeneic Graft versus Host Disease. Journal of Clinical Immunology, 37 (2), 197-266. doi:10.1007/s10875-017-0372-z

Ehx, G., SOMJA, J., Fransolet, G., Delens, L., Muller, J., BEGUIN, Y., Humblet-Baron, S., Hannon, M., & BARON, F. (10 February 2017). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Poster presentation]. 32nd General Annual Meeting of the Belgian Hematological Society, Bruxelles, Belgium.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (February 2017). Impact of Th17 population on xenogeneic graft-versus-host disease [Poster presentation]. 32nd General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

Ehx, G., SOMJA, J., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Hannon, M., Humblet-Baron, S., & BARON, F. (01 February 2017). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Paper presentation]. GIGA-Day 2017: New insights into the hallmark of cancer, Liège, Belgium.

Selleslag, D., Suciu, S., Meloni, G., Muus, P., Halkes, C. J. M., Venditti, A., Ramadan, S. M., Pruijt, H., Meert, L., Vignetti, M., Marie, J.-P., Wittnebel, S., de Witte, T., Amadori, S., Willemze, R., & Baron, F. (February 2017). Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial. Haematologica, 102 (2), 47-e51. doi:10.3324/haematol.2016.153130

Baron, F. (2017). Unrelated donor haemopoietic stem-cell transplantation: ATG or not? The Lancet Haematology, 4 (6), 252-e253. doi:10.1016/S2352-3026(17)30064-9

Baron, F., Mohty, M., Blaise, D., Socie, G., Labopin, M., Esteve, J., Ciceri, F., Giebel, S., Gorin, N. C., Savani, B. N., Schmid, C., & Nagler, A. (2017). Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 102, 224-234. doi:10.3324/haematol.2016.148510

Baron, F., & Nagler, A. (2017). Novel strategies for improving hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation or intensive chemotherapy. Expert Opinion on Biological Therapy, 163-174. doi:10.1080/14712598.2017.1269167

Baron, F., Ruggeri, A., Beohou, E., Labopin, M., Mohty, M., Blaise, D., Cornelissen, J. J., Chevallier, P., Sanz, G., Petersen, E., Savani, B. N., Gluckman, E., & Nagler, A. (2017). Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Journal of Hematology and Oncology, 10 (1), 128. doi:10.1186/s13045-017-0497-9

Canaani, J., Savani, B. N., Labopin, M., Michallet, M., Craddock, C., Socie, G., Volin, L., Maertens, J. A., Crawley, C., Blaise, D., Ljungman, P. T., Cornelissen, J., Russell, N., Baron, F., Gorin, N., Esteve, J., Ciceri, F., Schmid, C., Giebel, S., ... Nagler, A. (2017). ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. American Journal of Hematology, 93, 246-253. doi:10.1002/ajh.24771

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & BEGUIN, Y. (January 2017). UNE INJECTION UNIQUE DE CELLULES STROMALES MESENCHYMATEUSES AU JOUR 3 APRES GREFFE HEPATIQUE EST INSUFFISANTE POUR INDUIRE UNE TOLERANCE OPERATIONNELLE. Transplant International, 30 (suppl 1), 8 (O12.

Ehx, G., & Baron, F. (2017). Immune recovery predicts survival after T-cell depleted allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 58, 1774-1776. doi:10.1080/10428194.2017.1283688

Ehx, G., Fransolet, G., De Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (2017). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology, 6:e1314425. doi:10.1080/2162402X.2017.1314425

Farhat, K., Bodart, G., Martens, H., Baron, F., Beguin, Y., Moutschen, M., Salvatori, R., & Geenen, V. (2017). A surprising and dramatic neuroendocrine-immune phenotype of mice deficient in Growth Hormone-Releasing Hormone (GHRH). Neuroimmunomodulation.

GREGOIRE, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., BARON, F., LOUIS, E., & BEGUIN, Y. (2017). Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 45, 205-221. doi:10.1111/apt.13864

GREGOIRE, C., Louis, E., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., GIET, O., Beguin, Y., & BARON, F. (2017). The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn’s disease. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 730-753). Hoboken, United States: John Wiley & Sons, Inc.

Heusschen, R., Muller, J., WITHOFS, N., BARON, F., BEGUIN, Y., & CAERS, J. (2017). Multiple myeloma bone disease: from mechanisms to next generation therapy. Belgian Journal of Hematology, 8, 66-74.

Lee, C. J., Savani, B. N., Mohty, M., Labopin, M., Ruggeri, A., Schmid, C., Baron, F., Esteve, J., Gorin, N. C., Giebel, S., Ciceri, F., & Nagler, A. (2017). Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 102 (11), 1810-1822. doi:10.3324/haematol.2017.176107

Muffly, L., Pasquini, M. C., Martens, M., Brazauskas, R., Zhu, X., Adekola, K., Aljurf, M., Ballen, K. K., Bajel, A., Baron, F., Battiwalla, M., Beitinjaneh, A., Cahn, J.-Y., Carabasi, M., Chen, Y.-B., Chhabra, S., Ciurea, S., Copelan, E., D'Souza, A., ... Artz, A. (2017). Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood, 130 (9), 1156-1164. doi:10.1182/blood-2017-03-772368

Servais, S., & Baron, F. (2017). Chapitre: Maladie du greffon contre l'hôte chronique. In Mohty Mohamad & Brissot Eolia, Allogreffe de cellules souches hématopoïétiques - Manuel de pratique. LGM Sciences.

Shouval, R., Ruggeri, A., Labopin, M., Mohty, M., Sanz, G., Michel, G., Kuball, J., Chevallier, P., Al-Seraihy, A., Milpied, N.-J., de Heredia, C. D., Arcese, W., Blaise, D., Rocha, V., Fein, J., Unger, R., Baron, F., Bader, P., Gluckman, E., & Nagler, A. (2017). An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. Clinical Cancer Research, 23 (21), 6478-6486. doi:10.1158/1078-0432.CCR-17-0489

Ustun, C., Giannotti, F., Zhang, M.-J., Wang, H.-L., Brunstein, C., Labopin, M., Rocha, V., de Lima, M., Baron, F., Sandmaier, B. M., Eapen, M., Gluckman, E., Nagler, A., Weisdorf, D. J., & Ruggeri, A. (2017). Outcomes of UCB transplantation are comparable in FLT3+ AML: Results of CIBMTR, eurocord and EBMT collaborative analysis. Leukemia, 31, 1408-1414. doi:10.1038/leu.2017.42

Versluis, J., In 't Hout, F. E. M., Devillier, R., van Putten, W. L. J., Manz, M. G., Vekemans, M.-C., Legdeur, M.-C., Passweg, J. R., Maertens, J., Kuball, J., Biemond, B. J., Valk, P. J. M., van der Reijden, B. A., Meloni, G., Schouten, H. C., Vellenga, E., Pabst, T., Willemze, R., Lowenberg, B., ... Cornelissen, J. J. (2017). Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia, 31, 26-33. doi:10.1038/leu.2016.183

Vrancken, L., Delens, L., BEGUIN, Y., BARON, F., & SERVAIS, S. (2017). Focus sur les lymphocytes T dans la maladie du greffon contre l'hôte après allogreffe de cellules soucges hématopoïétiques: implications pour de nouvelles stratégies de prévention. OncoHemato : Revue Multidisciplinaire d'Oncologie et Hématologie, 11, 23-31.

Belle, L.* , Fransolet, G.* , Somja, J., BINSFELD, M., Delvenne, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G.* , & Baron, F.*. (12 December 2016). Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS ONE, 11, 0167997. doi:10.1371/journal.pone.0167997
* These authors have contributed equally to this work.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (08 December 2016). Xenogeneic graft-versus-host disease: Impact of Th17 cells [Poster presentation]. Journée des chercheurs Télévie 2017, Bruxelles, Belgium.

Fransolet, G., Belle, L., SOMJA, J., DELVENNE, P., Hannon, M., Drion, P., BINSFELD, M., BEGUIN, Y., Ehx, G., & Baron, F. (08 December 2016). Limited impact of imatinib in a murine model of sclerodermatous chronic graft-versus-host disease (scl-cGVHD) [Paper presentation]. Séminaire des chercheurs Télévie 2017, Bruxelles, Belgium.

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (18 November 2016). Impact des cellules Th17 sur la GVH xénogénique [Paper presentation]. 16ème édition du congrès de la SFGM-TC, Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, Liège, Belgium.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (18 November 2016). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Paper presentation]. Congrès Commun de la SFGM-TC et de la SFBCT, Liège, Belgium.

Belle, L., Fransolet, G., SOMJA, J., BINSFELD, M., DELVENNE, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G., & Baron, F. (17 November 2016). Limited impact of imatinib in a murine model of sclerodermic chronic graft-versus-host disease [Poster presentation]. 16ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) en commun avec la SFBCT, Liège, Belgium.

Farhat, K., Bodart, G., RENARD, J. D. C., Desmet, C., Moutschen, M., Baron, F., Beguin, Y., Salvatori, R., Geenen, V., & Martens, H. (November 2016). Severe deficiency of the somatotrope GHRH/GH/IGF1 axis induces a dramatic susceptibility to Streptococcus pneumoniae infection [Paper presentation]. 50e Congrès de la Société Française d'Immunologie (SFI), Paris, France.

SID, S., Baron, F., WILLEMS, E., Caers, J., Bonnet, C., DE PRIJCK, B., LEJEUNE, M., HAFRAOUI, K., Servais, S., JASPERS, A., & Beguin, Y. (November 2016). Hematologic recovery after autologus stem cell transplantation in multiple myeloma: a single center experience of 225 patients [Paper presentation]. 16ème Congrès commun de la SFGM-TC & 8ème de la SFBCT, Liège, Belgium.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (14 October 2016). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Poster presentation]. Regulatory T cell mini-symposium, Leuven, Belgium.

Ehx, G., Somja, J., Fransolet, G., Delens, L., Muller, J., Beguin, Y., Humblet-Baron, S., & Baron, F. (14 October 2016). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Poster presentation]. Regulatory T cells mini-symposium, Leuven, Belgium.

Giebel, S., Czyz, A., Ottmann, O., Baron, F., Brissot, E., Ciceri, F., Cornelissen, J., Esteve, J., Gorin, N., Savani, B., Schimd, C., Mohty, M., & Nagler, A. (October 2016). Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 122 (19), 2941-2951. doi:10.1002/cncr.30130

Fransolet, G.* , Ehx, G.* , SOMJA, J., Delens, L., Hannon, M., Muller, J., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., DELVENNE, P., BEGUIN, Y., Conteduca, G.* , & BARON, F.*. (04 July 2016). Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. Journal of Hematology and Oncology, 9, 53. doi:10.1186/s13045-016-0281-2
* These authors have contributed equally to this work.

Delens, L., BEGUIN, Y., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., SERVAIS, S., & BARON, F. (27 May 2016). Th17 cell population seems to aggravate xenogeneic graft-versus-host disease [Poster presentation]. 2016 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (March 2016). Azacytidine Enhances Regulatory T-Cells In Vivo and Prevents Experimental Xenogeneic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 22 (3), 393. doi:10.1016/j.bbmt.2015.11.917

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (29 January 2016). Salt but not glucocorticoïds enhances Th17 differentiation from naïve T cells in vitro [Poster presentation]. 31st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Ehx, G., Hannon, M., Humblet-Baron, S., DUBOIS, S., Daulne, C., Drion, P., BEGUIN, Y., & BARON, F. (29 January 2016). Immunomodulatory effects of rapamycin in Graft versus Host Disease [Poster presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Bruxelles, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Delens, L., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., DELVENNE, P., BEGUIN, Y., Conteduca, G., & Baron, F. (29 January 2016). Azacytidine and Decitabine prevent experimental sclerodermic chronic graft-versus-host disease [Poster presentation]. 31st general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Grégoire, C., Beguin, Y., Hannon, M., DUBOIS, S., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., Ehx, G., & Baron, F. (29 January 2016). Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice [Poster presentation]. 31th General Meeting of the Belgian Hematological Society.

Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., Magro, D., De Fabritiis, P., Muus, P., Alimena, G., Mancini, M., Hagemeijer, A., Paolini, F., Vignetti, M., Fazi, P., ... Baron, F. (2016). Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. Journal of Clinical Oncology, 34, 972-976. doi:10.1200/JCO.2015.64.0060

Baron, F., & Beguin, Y. (2016). Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time? Bone Marrow Transplantation, 51, 640-42. doi:10.1038/bmt.2016.38

Baron, F., & Nagler, A. (2016). Best allogeneic transplantation approach for AML patients in first CR: is delayed unrelated donor bone marrow transplantation better than immediate unrelated cord blood transplantation? European Journal of Haematology, 97, 215-216. doi:10.1111/ejh.12745

Baron, F., Ruggeri, A., & Nagler, A. (2016). Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. Expert Review of Hematology, 9, 297-314. doi:10.1586/17474086.2016.1128321

Binsfeld, M., Muller, J., Lamour, V., De Veirman, K., De Raeve, H., Bellahcene, A., Van Valckenborgh, E., BARON, F., BEGUIN, Y., CAERS, J., & Heusschen, R. (2016). Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget, 7, 37931-37943. doi:10.18632/oncotarget.9270

Göktuna, S., Shostak, K., Chau, T.-L., Heukamp, L., Hennuy, B., Duong, H. Q., LADANG, A., Close, P., Klevernic, I., Olivier, F., Florin, A., Ehx, G., Baron, F., Vandereyken, M., Rahmouni, S., Vereecke, L., van Loo, G., Büttner, R., Greten, F., & Chariot, A. (2016). The Prosurvival IKK-Related Kinase IKK« Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine. Cancer Research, 76, 2587-99. doi:10.1158/0008-5472.CAN-15-1473

Heusschen, R.* , Muller, J.* , Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., BEGUIN, Y., Menu, E., Cohen-Solal, M., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma. Oncotarget, 7, 30712-30729. doi:10.18632/oncotarget.8750
* These authors have contributed equally to this work.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Belgian Journal of Hematology.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Brussels, Belgium.

Humblet-Baron, S., Franckaert, D., Dooley, J., Bornschein, S., Cauwe, B., Schonefeldt, S., Bossuyt, X., Matthys, P., Baron, F., Wouters, C., & Liston, A. (2016). IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis. Journal of Allergy and Clinical Immunology, 138 (1), 200-209.e8. doi:10.1016/j.jaci.2015.12.1314

Lübbert, M., Suciu, S., Hagemeijer, A., Rüter, B., Platzbecker, U., Giagounidis, A., Selleslag, D., Labar, B., Germing, U., Salih, H. R., Muus, P., Pflüger, K.-H., Schaefer, H.-E., Bogatyreva, L., Aul, C., de Witte, T., Ganser, A., Becker, H., Huls, G., ... Wijermans, P. W. (2016). Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Annals of Hematology, 95, 191-199. doi:10.1007/s00277-015-2547-0

Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A., Aljurf, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J., Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A., ... Carreras, E. (2016). Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 51, 906-912. doi:10.1038/bmt.2016.130

Savani, B. N., Labopin, M., Blaise, D., Niederwieser, D., Ciceri, F., Ganser, A., Arnold, R., Afanasyev, B., Vigouroux, S., Milpied, N., Hallek, M., Cornelissen, J. J., Schwerdtfeger, R., Polge, E., Baron, F., Esteve, J., Gorin, N. C., Schmid, C., Giebel, S., ... Nagler, A. (2016). Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia–A report from the ALWP of the EBMT. Haematologica, 101, 256-262. doi:10.3324/haematol.2015.135699

SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235.

Shouval, R., Labopin, M., Unger, R., Giebel, S., Ciceri, F., Schmid, C., Esteve, J., Baron, F., Gorin, N. C., Savani, B., Shimoni, A., Mothy, M., & Nagler, A. (2016). Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. PLoS ONE, 11, 0150637. doi:10.1371/journal.pone.0150637

Tsirigotis, P., Byrne, M., Schmid, C., Baron, F., Ciceri, F., Esteve, J., Gorin, N. C., Giebel, S., Mohty, M., Savani, B. N., & Nagler, A. (2016). Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplantation, 51, 1431-1438. doi:10.1038/bmt.2016.167

Delens, L., Servais, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Daulne, C., Vrancken, L., Beguin, Y., & Baron, F. (03 December 2015). Revisiting Th17 cell subsets in the setting of allogeneic stem cell transplantation and (cortico-refractory) graft-versus-host disease [Poster presentation]. Journée Télévie 2016, Gembloux, Belgium.

Ehx, G., & BARON, F. (19 November 2015). Unraveling immune recovery after allogeneic hematopoietic stem cell transplantation: the contribution of flow cytometry [Paper presentation]. Advances in Immunomonitoring by Flow Cytometry, Antwerpen, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., Delvenne, P., BEGUIN, Y., Conteduca, G., & Baron, F. (19 November 2015). L'Azacytidine comme traitement de la maladie du greffon contre l'hôte de type chronique sclérodermique expérimentale [Paper presentation]. 15ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire, Clermont-Ferrand, France.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (13 November 2015). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Paper presentation]. EORTC Leukemia Group-GIMEMA meeting, Rome, Italy.

SHOUVAL, R., LABOPIN, M., BONDI, O., MISHAN-SHAMAY, H., CICERI, F., ESTEVE, J., GIEBEL, S., GORIN, N. C., SCHMID, C., POLGE, E., ALJURF, M., KROGER, N., CRADDOCK, C., BACIGALUPO, A., CORNELISSEN, J. J., BARON, F., UNGER, R., NAGLER, A., & MOHTY, M. (01 October 2015). Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. Journal of Clinical Oncology, 33 (28), 3144-3152. doi:10.1200/JCO.2014.59.1339

JASPERS, A., Baron, F., SERVAIS, S., LEJEUNE, M., WILLEMS, E., SEIDEL, L., HAFRAOUI, K., Bonnet, C., & Beguin, Y. (September 2015). Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival. American Journal of Hematology, 90 (9), 197-199. doi:10.1002/ajh.24100

SCHMID, C., LABOPIN, M., SOCIE, G., DAGUINDAU, E., VOLIN, L., HUYNH, A., BOURHIS, J. H., MILPIED, N., CORNELISSEN, J., CHEVALLIER, P., MAERTENS, J., JINDRA, P., BLAISE, D., LENHOFF, S., IFRAH, N., BARON, F., CICERI, F., GORIN, C., SAVANI, B., ... MOHTY, M. (September 2015). Outcome and risk factor analysis of molecular subgroups in cytogenetically normal AML treated by allogeneic transplantation. Blood, 126, 2062-2069.

HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374

Holter-Chakrabarty, J., Pierson, N., Zhang, M.-J., Zhu, X., Akpek, G., Aljurf, M., Artz, A., Baron, F., Bredeson, C., Dvorak, C., Epstein, R., Lazarus, H., Olsson, R., Selby, G., Williams, K., Cooke, K., Pasquini, M., & McCarthy, P. (July 2015). The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. Biology of Blood and Marrow Transplantation, 21 (7), 1251-7. doi:10.1016/j.bbmt.2015.03.017

JASPERS, A., Baron, F., Maertens, J., DE PRIJCK, B., Schots, R., Bonnet, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & Beguin, Y. (July 2015). Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation [letter to the editor]. American Journal of Hematology, 90 (7), 133-4. doi:10.1002/ajh.24013

BARON, F., LABOPIN, M., RUGGERI, A., MOHTY, M., MILPIED, N., BACIGALUPO, A., RAMBALDI, A., BONIFAZI, F., BOSI, A., SIERRA, J., YAKOUB-AGHA, I., SANTASUSANA, J., GLUCKMAN, E., & NAGLER, A. (2015). Unrelated cord blood (ECB) transplantation for AML: higher incidence of acute GVHD and lower survival in male patients transplanted with female unrelated cord blood. A report from Eurocord and the ALWP of the EBMT. Bone Marrow Transplantation.

SHOUVAL, R., LABOPIN, M., UNGER, R., GIEBEL, S., CICERI, F., SCHMID, C., ESTEVE, J., BARON, F., GORIN, N., SAVANI, B., MOHTY, M., & NAGLER, A. (March 2015). Exploring limiting factors in the prediction of allogeneic HSCT related mortality: an in-silico machine learning analysis of the acute leukemia working party (ALWP) registry of the EBMT. Bone Marrow Transplantation, 50, 2.

BINSFELD, M., Hannon, M., Humblet-Baron, S., Beguin, Y., Baron, F., & CAERS, J. (30 January 2015). Effects of the immunomodulating peptide thymosin alpha 1 in multiple myeloma and immune reconstitution after hematopoietic stem cell transplantation in murine models [Poster presentation]. 30th General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

Delens, L., SERVAIS, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Beguin, Y., & Baron, F. (30 January 2015). Effects of Tocilizumab on Th17 cell differentiation in a humanized mouse model of xenogeneic graft-versus-host disease [Poster presentation]. 30st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Belle, L., Drion, P., Humblet-Baron, S., Beguin, Y., & Baron, F. (30 January 2015). Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease [Poster presentation]. 30th general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Baron, F., Labopin, M., Peniket, A., Jindra, P., Afanasyev, B., Sanz, M., Deconinck, E., Nagler, A., & Mohty, M. (2015). Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer, 121, 1048-1055. doi:10.1002/cncr.29163

Baron, F., Labopin, M., Ruggeri, A., Mothy, M., Sanz, G., Milpied, N., Bacigalupuo, A., Rambaldi, A., Bonifazi, F., Bosi, A., Sierra, J., Yakoub-Agha, I., Ribera Santasusana, J. M., Gluckman, E., & Nagler, A. (2015). Unrelated cord blood transplantation for adult patients with acutemyeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival inmale patients transplantedwith female unrelated cord blood—a report from Eurocord, the Acute LeukemiaWorking Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. Journal of Hematology and Oncology, 8, 107. doi:10.1186/s13045-015-0207-4

Baron, F., Zachée, P., Maertens, J., Kerre, T., ORY, A., SEIDEL, L., Graux, C., Lewalle, P., Van Gelder, M., Theunissen, K., WILLEMS, E., Emonts, M.-P., De Becker, A., & Beguin, Y. (2015). Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Journal of Hematology and Oncology, 8, 4. doi:10.1186/s13045-014-0098-9

BECKER, H., SUCIU, S., RUTER, B. H., PLATZBECKER, U., GIAGOUNIDIS, A., SELLESLAG, D., LABAR, B., GERMING, U., SALIH, H. R., MUUS, P., PFLUGER, K.-H., HAGEMEIJER, A., SCHAEFER, H.-E., FIACCADORI, V., BARON, F., GANSER, A., AUL, C., DE WITTE, T., WIJERMANS, P. W., & LUBBERT, M. (2015). Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). Annals of Hematology, 94, 2003-2013. doi:10.1007/s00277-015-2489-6

Binsfeld, M., HANNON, M., Otjacques, E., Humblet-Baron, S., BAUDOUX, E., BEGUIN, Y., BARON, F., & CAERS, J. (2015). Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation. Cancer Immunology, Immunotherapy, 64, 989-998. doi:10.1007/s00262-015-1708-2

Cuende, J., Liénart, S., Dedobbeleer, O., van der Woning, B., De Boeck, G., Stockis, J., Huygens, C., Colau, D., SOMJA, J., Delvenne, P., Hannon, M., Baron, F., Dumoutier, L., Renauld, J.-C., De Haard, H., Saunders, M., Coulie, P., & Lucas, S. (2015). Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Science Translational Medicine, 7, 284ra56. doi:10.1126/scitranslmed.aaa1983

DE WITTE, T., SUCIU, S., MEERT, L., HALKES, C., SELLESLAG, D., BRON, D., AMADORI, S., WILLEMZE, R., MUUS, P., & BARON, F. (2015). Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). Annals of Hematology, 94, 1981-1989. doi:10.1007/s00277-015-2486-9

Ehx, G.* , Hannon, M.* , BEGUIN, Y., Humblet-Baron, S.* , & BARON, F.*. (2015). Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets. Oncotarget, 6, 43255-43266. doi:10.18632/oncotarget.6486
* These authors have contributed equally to this work.

Hengeveld, M., Suciu, S., Chelgoum, Y., Marie, J.-P., Muus, P., Lefrère, F., Mandelli, F., Pane, F., Amadori, S., Fioritoni, G., Labar, B., Baron, F., Cermak, J., Bourhis, J.-H., Storti, G., Fazi, P., Hagemeijer, A., Vignetti, M., Willemze, R., & de Witte, T. (2015). High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT. Bone Marrow Transplantation, 50, 341-347. doi:10.1038/bmt.2014.262

Humblet-Baron, S., & Baron, F. (2015). Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunology and Cell Biology, 89, 825-826. doi:10.1038/icb.2014.120

Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J.-H., Duarte, R., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., ... Carreras, E. (2015). Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 50, 781-789. doi:10.1038/bmt.2015.52

SERVAIS, S., Baron, F., & BEGUIN, Y. (2015). Impact of graft source and composition on outcomes after allogeneic stem cell transplantation. Belgian Journal of Hematology, 6 (4), 162-168.

SERVAIS, S., Menten-Dedoyart, C., Beguin, Y., SEIDEL, L., Gothot, A., Daulne, C., WILLEMS, E., Delens, L., Humblet-Baron, S., Hannon, M., & Baron, F. (2015). Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. PLoS ONE, 10 (6), 0130026. doi:10.1371/journal.pone.0130026

AMADORI, S., SUCIU, S., SELLESLAG, D., ROSSETTI, E., GAIDANO, G., MUSSO, M., ANNINO, L., VENDITTI, A., MAGRO, D., DE FABRITIIS, P., MUUS, P., ALIMENA, G., MANCINI, M., HAGEMEIJER, A., COTUGNO, F., VIGNETTI, M., FAZI, P., MEERT, L., RAMADAN, S. M., ... BARON, F. (December 2014). Improved overall survival with Gemtuzumab Ozogamicin (GO) compared with best supportive care (BSC) in elderly patients with untreated acute myeloid leukemia (AML) not considered fit for intensive chemotherapy: final results from the randomized phase III study (AML-19) of the EORTC and gimema leukemia groups. Blood, 124 (21), 619.

BARON, F., LABOPIN, M., PENIKET, A., JINDRA, P., AFANASYEV, B., SANZ, M. A., DECONINCK, E., NAGLER, A., & MOHTY, M. (December 2014). RIC allo-SCT with Flu/Bu in comparaison to Flu/Mel for AML results in similar overall survival: a report from the ALWP of the EBMT. Blood, 124 (21), 545.

BEGUIN, Y., ZACHEE, P., MAERTENS, J., KERRE, T., ORY, A., SEIDEL, L., GRAUX, C., LEWALLE, P., VAN GELDER, M., THEUNISSEN, K., WILLEMS, E., EMONDS, M.-P., DE BECKER, A., & BARON, F. (December 2014). Nonmyeloablative allogeneic hematopoietic cell transplantation following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Blood, 124 (21), 542.

DEVILLIER, R., LABOPIN, M., CHEVALLIER, P., LIOURE, B., SOCIE, G., HUYNH, A., BOURHIS, J.-H., CAHN, J.-Y., MICHALLET, M., VINCENT, L., BARON, F., BLAISE, D., NAGLER, A., & MOHTY, M. (December 2014). Higher doses of antithymocyte globulin (ATG) increase the risk of relapse in acute myeloid leukemia (AML) patients undergoing matched related donor allogeneic transplantation in first complete remission (CR1): an analysis from the acute leukemia working party of EBMT. Blood, 124 (21), 729.

JASPERS, A., BARON, F., MAERTENS, J., DE PRIJCK, B., SCHOTS, H., BONNET, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & BEGUIN, Y. (December 2014). Long-term safety follow-up of a rendomized trial of Darbepoetin Alpha and intravenous iron following autologous hematopoietic cell transplantation. Blood, 124 (21), 3948.

SELLESLAG, D. L. D., SUCIU, S., MELONI, G., MUUS, P., HALKES, C. J. M., VENDITTI, A., RAMADAN, S. M., PRUIJT, H., MEERT, L., VIGNETTI, M., MARIE, J.-P., BRON, D., DE WITTE, T., AMADORI, S., WILLEMZE, R., & BARON, F. (December 2014). Clofarabine in combination with a standard remission induction regimen in patients 18-60 years old previously untreated intermediate an bad risk actue myelogenous leukemia (AML) or high risk myelodysplasia (MDS): combined phase I/II results of the EORTC/Gimema AML-14A trial. Blood, 124 (21), 3675.

SHOUVAL, R., LABOPIN, M., UNGER, R., GIEBEL, S., CICERI, F., SCHMID, C., ESTEVE, J., BARON, F., SAVANI, B. N., MOHTY, M., & NAGLER, A. (2014). Prediction of allogeneic HSCT related mortality in acute leukemia: exploring boundaries of prediction through machine learning based modeling. A data mining study from the acute leukemia working party (ALWP) of the EBMT. Blood.

BARON, F. (November 2014). The role of ATG: Optimal dosage and timing? [Paper presentation]. Acute Leukemia, Paris, France.

MOERMANS, C., BONNET, C., WILLEMS, E., Baron, F., NGUYEN DANG, D., HENKET, M., Sele, J., CORHAY, J.-L., Beguin, Y., & Louis, R. (November 2014). Sputum cytokines levels in patients undergoing hematopoietic SCT (HSCT) and comparison with healthy subjects and COPD: a pilot study. Bone Marrow Transplantation, 49 (11), 1382-1388. doi:10.1038/bmt.2014.164

VALDES SOCIN, H. G., Potorac, I., DE PASQUAL, A., BARON, F., DE PRIJCK, B., Beguin, Y., & Beckers, A. (2014). Leucémie myéloblastique aiguë : sécrétion paranéoplasique de GH et de PRL ? In Abstract book - Annales d'Endocrinologie : 31ème Congrès de la Société Françaose d'Endocrinologie, Lyon 5-8 novembre 2014.

De Bock, M., BEGUIN, Y., Leprince, P., WILLEMS, E., BARON, F., Deroyer, C., Seidel, L., CAVALIER, E., DE SENY, D., MALAISE, M., GOTHOT, A., MERVILLE, M.-P., & Fillet, M. (July 2014). Comprehensive plasma profiling for the characterization of graft-versus-host disease biomarkers. Talanta, 125, 265-275. doi:10.1016/j.talanta.2014.03.017

Hannon, M., LECHANTEUR, C., Lucas, S., Somja, J., Seidel, L., Belle, L., Bruck, F., BAUDOUX, E., GIET, O., Chantillon, A.-M., Delvenne, P., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (17 June 2014). Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. Transfusion, 54 (February), 353-363. doi:10.1111/trf.12279

BARON, F. (March 2014). Impact of ATG on outcome after reduced-intensity conditioning and clinical case discussion [Paper presentation]. 40th Annual Meeting of the European Society for Blood and Marrow transplantation, Milan, Italy.

JASPERS, A., Baron, F., WILLEMS, E., Seidel, L., Wiegerinck, E. T., Swinkels, D. W., & BEGUIN, Y. (March 2014). Serum hepcidin following autologous hematopoietic cell transplantation : an illustration of the interplay of iron status, erythropoiesis and inflammation [letter to the editor]. Haematologica, 99 (3), 35-37. doi:10.3324/haematol.2013.100032

SHOUVAL, R., LABOPIN, M., BONDI, O., MISHAN-SHAMAY, H., SHIMONI, A., CICERI, F., ESTEVE, J., GIEBEL, S., GORIN, N.-C., SCHMID, C., ZAKARIA, I., MOUKHTARI, L., POLGE, E., ALJURF, M., KROGER, N., CRADDOCK, C., BACIGALUPO, A., CORNELISSEN, J., BARON, F., ... MOHTY, M. (March 2014). Machine learning based predictive modeling for mortality 100 days post allogeneic hematopoietic stem cell transplantation (ALLO-HSCT) in acute leukemia: an EBMT-acute leukemia working party (ALWP) registry study. Bone Marrow Transplantation, 49, 39.

Warlick, E., Paulson, K., Brazauskas, R., Zhong, X., Miller, A., Camitta, B., George, B., Savani, B., Ustun, C., Marks, D., Waller, E., Baron, F., Freytes, C., Socie, G., Akpek, G., Schouten, H., Lazarus, H., Horwitz, E., Koreth, J., ... Litzow, M. (February 2014). Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biology of Blood and Marrow Transplantation, 20 (2), 202-208. doi:10.1016/j.bbmt.2013.10.023

Ehx, G., HANNON, M., DUBOIS, S., HALLEUX, A., Belle, L., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (27 January 2014). Immunomodulatory effects of Rapamycin in xenogeneic GVHD [Poster presentation]. GIGA Day 2014, Liège, Belgium.

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9

Baron, F., Labopin, M., Blaise, D., Lopez-Corral, L., Vigouroux, S., Craddock, C., Attal, M., Jindra, P., Goker, H., Socié, G., Chevallier, P., Browne, P., Sandstedt, A., Duarte, R., Nagler, A., & Mohty, M. (2014). Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning all-SCT from a HLA-identical sibling donor : a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 49, 389-396. doi:10.1038/bmt.2013.204

Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. Belgian Journal of Hematology.

Binsfeld, M., Beguin, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Heusschen, R., Drion, P., Zilberberg, J., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS ONE, 113764. doi:10.1371/journal.pone.0113764

Binsfeld, M., Fostier, K., Muller, J., Baron, F., Schots, R., Beguin, Y., Heusschen, R., & CAERS, J. (2014). Cellular immunotherapy in multiple myeloma : lessons from preclinical models. Biochimica et Biophysica Acta. Reviews on Cancer, 1846, 392-404. doi:10.1016/j.bbcan.2014.08.001

Binsfeld, M., Heusschen, R., Lamour, V., Van Valckenborgh, E., Bellahcene, A., Baron, F., BEGUIN, Y., & CAERS, J. (2014). Multiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines. Belgian Journal of Hematology.

Fransolet, G., Belle, L., SOMJA, J., Humblet-Baron, S., DUBOIS, S., Delvenne, P., Beguin, Y., & Baron, F. (January 2014). Imatinib improves survival of chronic Graft-versus-host disease by inhibiting TGF-β and PDGF-R in mice [Poster presentation]. 29th general annual meeting of the Belgian Hematological Society, Ghent, Belgium.

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Bonnet, C., & Beguin, Y. (2014). Long-term survival in patients receiving rhEPO following allogeneic hematopoietic cell transplantation. Belgian Journal of Hematology, 14.

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2014). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomized trial. Blood, 124, 33-41. doi:10.1182/blood-2014-01-546333

LAYIOS, N., CANIVET, J.-L., Baron, F., Moutschen, M., & Hayette, M.-P. (2014). Mortierella wolfii-Associated Invasive Disease. Emerging Infectious Diseases, 20 (9), 1591-2. doi:10.3201/eid2009.140469

MOERMANS, C., LECHANTEUR, C., BAUDOUX, E., GIET, O., HENKET, M., SEIDEL, L., LEJEUNE, M., WILLEMS, E., Baron, F., LOUIS, R., & BEGUIN, Y. (2014). Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning. Transplantation, 98 (3), 348-353. doi:10.1097/TP.0000000000000068

Belle, L., Ehx, G., SOMJA, J., Binsfeld, M., HANNON, M., CAERS, J., Fransolet, G., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease [Poster presentation]. 55th Annual Meeting of the American Society of Hematology.

Belle, L., Ehx, G., SOMJA, J., BINSFELD, M., Hannon, M., Caers, J., Fransolet, G., Beguin, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease. Blood, 122 (21), 4474.

BECKER, H., SUCIU, S., RUTER, B., PLATZBECKER, U., GIAGOUNIDIS, A., SELLESLAG, D., LABAR, B., GERMING, U., SALIH, H. R., MUUS, P., PFLUGER, K.-H., HAGEMEIJER, A., SCHAEFER, H.-E., BARON, F., GANSER, A., AUL, C., DE WITTE, T., WIJERMANS, P. W., & LUBBERT, M. (November 2013). Low-dose Decitabine Vs best supportive care in older patients with AML and low blast counts: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC leukemia cooperative group and german MDS study group. Blood, 122 (21), 1452.

RAMADAN, S. M., SUCIU, S., STEVENS-KROEF, M. J. P. L., WILLEMZE, R., AMADORI, S., DE WITTE, T., LOWENBERG, B., MUUS, P., LABAR, B., MEERT, L., DE SCHAETZEN, G., MELONI, G., LEONE, G., VIGNETTI, M., MANDELLI, F., BARON, F., & MARIE, J.-P. (November 2013). Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials. Blood, 122 (21), 829.

SHOUVAL, R., LABOPIN, M., BONDI, O., SHAMAY, H. M., SHIMONI, A., CICERI, F., ESTEVE, J., GIEBEL, S., GORIN, N.-C., SCHMID, C., ZAKARIA, I., MOUKHTARI, L., POLGE, E., AL-JURF, M., KROGER, N., CRADDOCK, C., BACIGALUPO, A., CORNELISSEN, J., BARON, F., ... MOTHY, M. (November 2013). Prediction of allogeneic hematopoietic stem cell transplantation (allo-HSCT) related mortality in acute leukemia: generation of a machine learning-based model using the data set of the acute leukemia working party (ALWP) of the EBMT. Blood, 122 (21).

LAYIOS, N., HAYETTE, M.-P., HUWART, A., JOSKIN, J., BLETARD, N., BARON, F., & MOUTSCHEN, M. (September 2013). First report of Mortierella wolfii causing human disease [Poster presentation]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

LAYIOS, N., HAYETTE, M.-P., HUWART, A., JOSKIN, J., BLETARD, N., BARON, F., & MOUTSCHEN, M. (September 2013). First report of Mortierella wolfii causing human disease [Paper presentation]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., BARON, F., & CAERS, J. (April 2013). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation [Poster presentation]. 3rd International Conference "Cancer Immunotherapy and Immunomonitoring (CITIM)", Cracovie, Poland.

Bruck, F.* , Belle, L.* , LECHANTEUR, C., de Leval, L., Hannon, M., DUBOIS, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., Beguin, Y., BRIQUET, A.* , & Baron, F.*. (March 2013). Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy, 15 (3), 267-279. doi:10.1016/j.jcyt.2012.09.003
* These authors have contributed equally to this work.

Belle, L., BINSFELD, M., DUBOIS, S., Hannon, M., Caers, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (February 2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin. Biology of Blood and Marrow Transplantation, 19, 317.

Bonnet, C., MENTEN, C., LAMBERT, F., Gothot, A., Baron, F., CAERS, J., HERENS, C., & Beguin, Y. (25 January 2013). Simultaneous diagnosis of CLL and CML in a single patient with evidence for two different cell clones [Poster presentation]. BHS, General Annual Meeting.

BEGUIN, Y., Maertens, J., DE PRIJCK, B., Schots, R., Seidel, L., BONNET, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., SERVAIS, S., JASPERS, A., FILLET, G., & BARON, F. (2013). Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation : A prospective multicenter randomized trial. American Journal of Hematology, 88, 990-996. doi:10.1002/ajh.23552

Belle, L., Binsfeld, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin [Poster presentation]. BMT Tandem Meetings (ASBMT), Salt Lake City, United States.

Belle, L., Binsfeld, M., HANNON, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease. Belgian Journal of Hematology.

Belle, L., Binsfeld, M., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & BARON, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease [Paper presentation]. 28th General Meeting of the Belgian Hematological Society.

Binsfeld, M., Otjacques, E., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & CAERS, J. (2013). The Immunomodulating Peptide Thymosin Alpha 1 Has no Effect on Multiple Myeloma Evolution and on Immune Reconstitution. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 41.

De Bock, M., Fillet, M., Hannon, M., Seidel, L., Merville, M.-P., Gothot, A., Beguin, Y., & Baron, F. (2013). Kinetics of IL-7 and IL-15 Levels after Allogeneic Peripheral Blood Stem Cell Transplantation following Nonmyeloablative Conditioning. PLoS ONE, 8 (2), 55876. doi:10.1371/journal.pone.0055876

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Theunissen, K., Daulne, C., Willems, E., Belle, L., Binsfeld, M., Gothot, A., Beguin, Y., & Baron, F. (2013). Comparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 38.

Hannon, M., LECHANTEUR, C., Somja, J., Lucas, S., Belle, L., Bruck, F., Baudoux, E., Beguin, Y., Humblet-Baron, S., & Baron, F. (2013). Infusion of CliniMACS (Myltenyi Biotec) Enriched Regulatory T Cells Delays Experimental Xenogeneic Graft-versus-Host Disease. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 15.

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2013). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial. Belgian Journal of Hematology, 16.

Moermans, C., Poulet, C., HENKET, M., Bonnet, C., WILLEMS, E., Baron, F., Beguin, Y., & Louis, R. (2013). Lung function and airway inflammation monitoring after hematopoietic stem cell transplantation. Respiratory Medicine, 107, 2071-2080. doi:10.1016/j.rmed.2013.10.013

SERVAIS, S., Beguin, Y., & Baron, F. (2013). Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Emerging Drugs, 18 (2), 173-192. doi:10.1517/14728214.2013.798642

SERVAIS, S., WILLEMS, E., Beguin, Y., & Baron, F. (2013). Allogreffe de cellules souches hématopoïétiques chez le patient âgé : jusqu'à quel âge ? Revue Médicale de Liège, 68 (1), 38-43.

Baron, F., Labopin, M., Niederwieser, D., Vigouroux, S., Cornelissen, J., Malm, C., Vindelov, L., Blaise, D., Janssen, J., Petersen, E., Socié, G., Nagler, A., Rocha, V., & Mohty, M. (December 2012). Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia : a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia, 26 (12), 2462-2468. doi:10.1038/leu.2012.135

Menten, C., Faccinetto, C., Golovchenko, M., Dupiereux-Fettweis, I., Van Lerberghe, P.-B., DUBOIS, S., Desmet, C., Elmoualij, B., Baron, F., Rudenko, N., Oury, C., Heinen, E., & Couvreur, B. (December 2012). Neutrophil Extracellular Traps (NET) Entrap and Kill Borrelia burgdorferi sensu stricto Spirochetes and Are not Affected by Ixodes ricinus Tick Saliva. Journal of Immunology, 189 (11), 5393-5401. doi:10.4049/jimmunol.1103771

Belle, L., BINSFELD, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humbelt-Baron, S., & BARON, F. (April 2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice. Bone Marrow Transplantation, 47 Suppl 1.

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (February 2012). Longitudinal Monitoring of Immune Reconstitution after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): Impact of T-Cell Depletion of the Graft. Biology of Blood and Marrow Transplantation, 18 (2), 274-S275. doi:10.1016/j.bbmt.2011.12.193

Baron, F., Labopin, M., Mufti, G., Arnold, R., Craddock, C., Bilger, K., Kroger, N., Nagler, A., & Mohty, M. (2012). Impact of alemtuzumab versus anti-thymocyte globulin after unrelated allogeneic stem cell transplantation with reduced-intensity conditioning as treatment for AML in CR1: a survey from the Acute Leukaemia Working Party of the EBMT [Paper presentation]. 38th EBMT Annual Meeting.

Baron, F., Labopin, M., Niederwieser, D., Vigouroux, S., Cornelissen, J., Malm, C., Vindelov, L., Blaise, D., Janssen, J., Petersen, E., Socie, G., Nagler, A., Rocha, V., & Mohty, M. (2012). Impact of chronic graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukaemia: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation [Paper presentation]. 38th EBMT Annual Meeting.

Baron, F., & SERVAIS, S. (2012). Rituximab et maladie du greffon contre l'hôte chronique. Horizons Hemato, 2 (2), 78-81.

Baron, F., & Storb, R. (2012). Mesenchymal stromal cells : a new tool against graft-versus-host disease ? Biology of Blood and Marrow Transplantation, 18 (6), 822-840. doi:10.1016/j.bbmt.2011.09.003

Baron, F., Suciu, S., Amadori, S., Muus, P., Zwierzina, H., Denzlinger, C., Delforge, M., Thyss, A., Selleslag, D., Indrak, K., Ossenkoppele, G., & De Witte, T. (2012). Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica, 97 (4), 529–533. doi:10.3324/haematol.2011.044347

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., Briquet, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice [Paper presentation]. 38th EBMT Annual Meeting.

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin Prevents Experimental Sclerodermatous Chronic Graft-versus-Host Disease in mice [Paper presentation]. 27th General Meeting of the Belgian Hematological Society.

Belle, L., Bruck, F., FOGUENNE, J., GOTHOT, A., BEGUIN, Y., Baron, F., & Briquet, A. (2012). Imatinib and Nilotinib Inhibit Hematopoietic Progenitor Cell Growth, but Do Not Prevent Adhesion, Migration and Engraftment of Human Cord Blood CD34+ Cells. PLoS ONE, 7 (12), 52564. doi:10.1371/journal.pone.0052564

Belle, L., Bruck, F., FOGUENNE, J., GOTHOT, A., BEGUIN, Y., BARON, F., & BRIQUET, A. (2012). Imatinib and Nilotinib do not prevent adhesion and migration of human CD34+ in vitro and in immunodeficient mice [Poster presentation]. Belgian Hematological Society Annual Meeting.

Belle, L., Bruck, F., FOGUENNE, J., Gothot, A., Beguin, Y., Baron, F., & BRIQUET, A. (2012). Imatinib and Nilotinib do not prevent adhesion and migration of human CD34+ in vitro and in immunodeficient mice. Belgian Journal of Hematology.

Binsfeld, M., Belle, L., Hannon, M., DUBOIS, S., Otjacques, E., Beguin, Y., Baron, F., & CAERS, J. (2012). Adaptation of a Murine Chronic GVH Model to Study Graft versus Myeloma Effect after Allogeneic Transplantation. Belgian Journal of Hematology, Abstracts book (Supplement of 27th General Meeting of the Belgian Hematological Society), 16.

Binsfeld, M., Belle, L., Hannon, M., Hofgaard, Dubois, S., Otjacques, E., BEGUIN, Y., Bogen, BARON, F., & CAERS, J. (2012). Adaptation of a murine chronic GvH model to study graftversus- myeloma effect after allogeneic transplantation. Bone Marrow Transplantation, 47 (Suppl.1).

Bruck, F., de Leval, L., Belle, L., LECHANTEUR, C., Hannon, M., BRIQUET, A., Dubois, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., BEGUIN, Y., & BARON, F. (2012). Bone marrow-derived mesenchymal stromal cells failed to prevent experimental xenogeneic graft-versus-host disease [Poster presentation]. Belgian Hematological Society General Annual Meeting.

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Theunissen, K., Daulne, C., Willems, E., Belle, L., Binsfeld, M., Gothot, A., Beguin, Y., & Baron, F. (2012). Comparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning. Haematologica, 97 (Supplement 1), 180.

Kermani, H., Goffinet, L., Mottet, M., Bodart, G., Morrhaye, G., Dardenne, O., Overbergh, L., Baron, F., Beguin, Y., Geenen, V., & Martens, H. (2012). Expression of growth hormone (GH)/insulin-like growth factor (IGF) axis during Balb/c ontogeny and effects of GH upon ex-vivo T-cell differentiation. Neuroimmunomodulation, 19, 137-147.

MENTEN, C., Castermans, E., Hannon, M., Ormenese, S., Beguin, Y., & Baron, F. (2012). What is the Contribution of Host-Derived CMV Immunity after Allogeneic Transplantation following Non-Myeloablative Conditioning? Haematologica, 97 (Supplement 1), 720.

MENTEN, C., Castermans, E., Hannon, M., Ormenese, S., Beguin, Y., & Baron, F. (2012). Evidence for Expansion of Host-derived CMV-specific CD8+ T cells after Allogeneic Transplantation with Non-Myeloablative Conditioning. Belgian Journal of Hematology, Abstracts book (Supplement of 27th General Meeting of the Belgian Hematological Society), 16.

SERVAIS, S., & Baron, F. (2012). Allogreffe de cellules souches hématopoïétiques après conditionnements réduits ("minigreffes") comme traitement de certaines pathologies hématologiques malignes. OncoHemato : Revue Multidisciplinaire d'Oncologie et Hématologie, 6, 6-12.

Willemze, R., Suciu, S., Marie, J.-P., Karrasch, M., Jansen, J., Amadori, S., Muus, P., Labar, B., Baron, F., Selleslag, D., Wijermans, P., Bron, D., Hagemeijer, A., Meloni, G., Lübbert, M., & de Witte, T. (2012). EORTC Leukemia Group achievements. EJC Supplements, I, 94-98. doi:10.1016/S1359-6349(12)70017-4

Bruck, F., Baron, F., DUBOIS, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., Beguin, Y., & Humblet-Baron, S. (February 2011). Rapamycin Delays Xenogeneic Acute Graft Versus Host Disease (aGVHD) in Nod/Scid/Il2RγNull (NSG) Mice: Impact of Regulatory T Cells [Poster presentation]. ASBMT meeting 2011. doi:10.1016/j.bbmt.2010.12.535

Baron, F., Labopin, M., Niederwieser, D., Milpied, N.-J., Cornelissen, J., Malm, C., Vindelov, L., Blaise, D., Janssen, J., Petersen, E., Socie, G., Vanderson, R., Nagler, A., & Mohty, M. (2011). Impact of chronic graft-versus-host disease (GVHD) after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) as treatment for acute myeloid leukemia (AML) : a survey from the Acute Leukemia Working Party of the EBMT. Blood, 118.

Belle, L., Baron, F., Bruck, F., Hannon, M., Servais, S., Beguin, Y., & BRIQUET, A. (2011). Despite Inhibitory Effects on Normal Hematopoiesis in Vitro, Imatinib and Nilotinib do not Prevent Engraftment of Human CD34+ HSCs in immunodeficient NSG Mice [Poster presentation]. 26th General Meeting of the Belgian Hematological Society.

Belle, L., Baron, F., Bruck, F., Hannon, M., SERVAIS, S., Beguin, Y., & BRIQUET, A. (2011). Despite inhibitory effects on normal hematopoiesis in vitro, Imatinib and Nilotinib do not prevent engraftment of human CD34+ HSCs in immunodeficient NSG mice. Belgian Journal of Hematology.

Bruck, F., BARON, F., Dubois, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., BEGUIN, Y., & Humblet-Baron, S. (2011). The mTor inhibitor rapamycin delays xenogeneic acute graft versus host disease (aGVHD) in NOD/SCID/IL2rgnull mice (NSG): impact of regulatory T cells [Poster presentation]. Belgian Hematological Society Annual General Meeting.

Bruck, F., BARON, F., Dubois, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., BEGUIN, Y., & Humblet-Baron, S. (2011). Rapamycin delays xenogeneic acute graft-versus-host disease (aGvHD) in NOD/SCID/IL2Rg NULL (NSG) mice: impact of regulatory T cells [Poster presentation]. ASBMT 2011.

CASTERMANS, E., Hannon, M., Dutrieux, J., Humblet, S., Seidel, L., Cheynier, R., Willems, E., Gothot, A., Vanbellinghen, J.-F., Geenen, V., Sandmaier, B. M., Storb, R., Beguin, Y., & Baron, F. (2011). Thymic recovery after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning is limited to patients younger than 60 years of age. Haematologica, 96(2), 298-306. doi:10.3324/haematol.2010.029702

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Daulne, C., Willems, E., Gothot, A., Beguin, Y., & Baron, F. (2011). Comparison of Immune Reconstitution after Non-myeloablative Hematopoietic Cell Transplantation (HCT) with Flu-TBI versus TLI-ATG Conditioning. Belgian Journal of Hematology, Abstracts book (Supplement of 26th General Meeting of the Belgian Hematological Society), 8.

Humblet, S., Baron, F., & Liston, A. (2011). Regulatory T cells fulfil their promise ? Immunology and Cell Biology, 89, 825-826. doi:10.1038/icb.2011.52

SERVAIS, S., Baron, F., & Beguin, Y. (2011). Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning. Transfusion and Apheresis Science, 44, 205-210. doi:10.1016/j.transci.2011.01.019

Servais, S., Beguin, Y., & Baron, F. (2011). Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation (HSCT). Belgian Journal of Hematology, 2, 3-9.

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (2011). Longitudinal Monitoring of Immune Reconstitution After Allogeneic Peripheral Blood Stem Cell Transplantation (HSCT): Impact of T Cell Depletion of the Graft. Belgian Journal of Hematology, Abstracts book (Supplement of 26th General Meeting of the Belgian Hematological Society), 31.

Kermani, H., Goffinet, L., Mottet, M., Renard, Dardenne, O., Baron, F., Beguin, Y., Geenen, V., & Martens, H. (September 2010). Expression of components of the growth hormone (GH)/insulin-like growth factor (IGF) axis during Balb/c mouse thymus ontogeny and effects of GH upon ex-vivo T-cell differentiation [Poster presentation]. Congress 2010 of the European Neuroendocrine Association (ENEA), Liège, Belgium.

Baron, F., & Beguin, Y. (2010). Hematopoietic stem cell transplantation in the treatment strategy of acute leukemia. Belgian Journal of Medical Oncology, 4, 118-123.

Baron, F., & Beguin, Y. (2010). GVHD chronique et effet anti-tumoral. Correspondance en Onco-Hématologie, 5, 12-16.

Baron, F., Lechanteur, C., Willems, E., Bruck, F., Baudoux, E., Seidel, L., Vanbellinghen, J.-F., Hafraoui, K., LEJEUNE, M., Gothot, A., Fillet, G., & Beguin, Y. (2010). Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 16 (6), 838-47. doi:10.1016/j.bbmt.2010.01.011

Hannon, M., Castermans, E., Cheynier, R., Seidel, L., Humblet-Baron, S., Willems, E., Gothot, A., Geenen, V., Sandmaier, B., Storb, R., Beguin, Y., & Baron, F. (2010). Thymic Recovery after Allogeneic Hematopoietic Cell Transplantation with non-Myeloablative Conditioning might Be Limited to Patients Younger than 60 Years of Age [Paper presentation]. 26th General Meeting of the Belgian Hematological Society.

Jaspers, A., Baron, F., Bonnet, C., De Prijck, B., Fassotte, M.-F., & Beguin, Y. (2010). Le lymphome du manteau. Revue Médicale de Liège, 65, 171-176.

Servais, S., Caers, J., Warling, O., Frusch, N., Baron, F., De Prijck, B., & Beguin, Y. (2010). Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma. British Journal of Haematology, 150 (3), 379-381. doi:10.1111/j.1365-2141.2010.08202.x

Servais, S., Willems, E., Beguin, Y., & Baron, F. (2010). Maladie du greffon contre l'hôte chronique : une prise en charge multidisciplinaire. Revue Médicale de Liège, 65, 81-87.

Willems, E.* , Baron, F.* , Seidel, L., Frère, P., Fillet, G., & Beguin, Y. (2010). Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplantation, 45, 689-693. doi:10.1038/bmt.2009.230
* These authors have contributed equally to this work.

Willems, E., Humblet-Baron, S., Dengis, O., Seidel, L., Beguin, Y., & Baron, F. (2010). Elevations of tumor necrosis factor-receptor-1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transplantation, 45, 1442-1448. doi:10.1038/bmt.2009.360

Humblet-Baron, S., CASTERMANS, E., Vanbellinghen, J.-F., Hannon, M., Jacobs, N., WILLEMS, E., Ormenese, S., Beguin, Y., & Baron, F. (February 2009). What Is The Role For Regulatory T-Cells After Nonmyeloablative Conditioning? Biology of Blood and Marrow Transplantation, 15 (2), 122-123. doi:10.1016/j.bbmt.2008.12.377

Baron, F., Petersdorf, E. W., Gooley, T., Sandmaier, B. M., Malkki, M., Chauncey, T. R., Maloney, D. G., & Storb, R. (2009). What is the role for donor natural killer cells after nonmyeloablative conditioning? Biology of Blood and Marrow Transplantation, 15 (5), 580-8. doi:10.1016/j.bbmt.2009.01.018

Baron, F., & Sandmaier, B. (2009). Immunobiology of reduced intensity conditioning in hematopoietic stem cell transplantation. In Hematology education : the education program for the annual congress of the European Hematology Association (pp. 242-249). Haematologica.

Baron, F., WILLEMS, E., LECHANTEUR, C., BAUDOUX, E., Frere, P., Vanbellinghen, J., Bruck, F., Gothot, A., HAFRAOUI, K., Fillet, G., & Beguin, Y. (2009). Co-transplantation of mesenchymal stem cells might mitigate acute GvHD without abrogating graftversus- tumour alloreactivity after allogeneic transplantation with non-myeloablative conditioning [Paper presentation]. 35th EBMT Annual Meeting.

Beguin, Y., Maertens, J., DE PRIJCK, B., Schots, R., Frère, P., Bonnet, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., LEJEUNE, M., SERVAIS, S., THeunissen, K., Fillet, G., & Baron, F. (2009). A prospective randomized multicenter trial of darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation [Poster presentation]. 24th General Meeting of the Belgian Hematological Society, Oostende, Belgium.

Castermans, E., Hannon, M., Cheynier, R., Seidel, L., Humblet-Baron, S., WILLEMS, E., Corbier, S., Gothot, A., Geenen, V., Sandmaier, B. M., Storb, R. F., Beguin, Y., & Baron, F. (2009). Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age. Blood, 114 (22), 1149.

Castermans, E., Hannon, M., Drion, P., Geenen, V., Beguin, Y., & Baron, F. (2009). Reconstitution du système immunitaire après allogreffe de cellules souches hématopoïétiques. Revue Médicale de Liège, 64 (S1), 2-8.

Dugauquier, C., Bataille, Y., Willems, E., Frere, P., De Prijck, B., Beguin, Y., & Baron, F. (2009). Toxoplasmore cérébrale compliquant une mini-allogreffe de cellules souches hématopoïétiques du sang périphérique. Revue Médicale de Liège, 64 (7-8), 366-369.

Hafraoui, K., Beguin, Y., & Baron, F. (2009). Cancers secondaires après allogreffe de cellules souches hématopoïétiques. Revue Médicale de Liège, 64 (10), 496-499.

Morrhaye, G., Kermani, H., Legros, J.-J., Baron, F., Beguin, Y., Moutschen, M., Cheynier, R., Martens, H., & Geenen, V. (2009). Impact of growth hormone (GH) deficiency and GH replacement upon thymus function in adult patients. PLoS ONE, 4 (5), 5668. doi:10.1371/journal.pone.0005668

Willems, E.* , Baron, F.* , Baudoux, E., Wanten, N., Seidel, L., Vanbellinghen, J.-F., Herens, C., Gothot, A., Frere, P., Bonnet, C., Hafraoui, K., Vanstraelen, G., Fillet, G., & Beguin, Y. (2009). Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial. Leukemia, 23 (3), 608-10. doi:10.1038/leu.2008.248
* These authors have contributed equally to this work.

Humblet-Baron, S., CASTERMANS, E., Vanbellighen, J.-F., Hannon, M., Jacobs, N., Beguin, Y., & Baron, F. (February 2008). What is the Role for Regulatory T-Cells after Nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 14 (2), 136-137. doi:10.1016/j.bbmt.2007.12.383

Baron, F., Appelbaum, F., & Sandmaier, B. (2008). Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. Innovative Leukemia and Lymphoma Therapy, 539-561.

Baron, F., & Sandmaier, B. (2008). Nonmyeloablative Transplantation. In Hematopoietic Stem Cell Transplantation (pp. 349-374). Soiffier SJ.

Castermans, E.* , Baron, F.* , Willems, E., Schaaf-Lafontaine, N., Meuris, N., Gothot, A., Vanbellinghen, J.-F., Herens, C., Seidel, L., Geenen, V., Cheynier, R., & Beguin, Y. (2008). Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica, 93 (2), 240-7. doi:10.3324/haematol.11708
* These authors have contributed equally to this work.

Lejeune, M., Beguin, Y., De Prijck, B., Fassotte, M.-F., Fillet, G., & Baron, F. (2008). Comment je traite...La leucémie myéloblastique aiguë (LMA) du sujet age en bon état général. Revue Médicale de Liège, 63 (2), 59-63.

Sorror, M. L., Leisenring, W., Mielcarek, M., Baron, F., Diaconescu, R., Hogan, W. J., Graves, S. S., & Storb, R. (2008). Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 gray total body irradiation. Transplantation, 85 (7), 1023-9. doi:10.1097/TP.0b013e318169be24

Baron, F., Sandmaier, B. M., Storer, B. E., Maris, M. B., Langston, A. A., Lange, T., Petersdorf, E., Bethge, W., Maziarz, R. T., McSweeney, P. A., Pulsipher, M. A., Wade, J. C., Chauncey, T. R., Sbizuru, J. A., Sorror, M. L., Woolfrey, A. E., Maloney, D. G., & Storb, R. (September 2007). Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 13 (9), 1041-1048. doi:10.1016/j.bbmt.2007.05.011

Baron, F., & Storb, R. (March 2007). Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Current Opinion in Hematology, 14 (2), 145-151. doi:10.1097/MOH.0b013e3280168462

Baron, F. (2007). Allogreffe de cellules souches hématopoïétiques après un conditionnement non-myéloablateur ("minigreffe") : remplacer les fortes doses de chimio/radiothérapie par l'effet de la greffe contre la tumeur [Post doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/102193

Baron, F., & Gothot, A. (2007). Les cellules souches mesenchymateuses: une nouvelle therapeutique polyvalente. Revue Médicale de Liège, 62 Spec No, 9-14.

Baron, F., Petersdorf, E., Sandmaier, B., Gooley, T., Malkki, M., Maloney, D., & Storb, R. (2007). What is the role for donor NK cells after nonmyeloablative conditioning ? Blood, 110.

Castermans, E., Morrhaye, G., Marchand, S., Martens, H., Moutschen, M., Baron, F., Beguin, Y., & Geenen, V. (2007). Evaluation clinique de la fonction du thymus. Revue Médicale de Liège, 62 (11), 675-8.

Castermans, E., Morrhaye, G., Marchand, S., Martens, H., Moutschen, M., Geenen, V., Beguin, Y., & Baron, F. (2007). Evaluation de la thymopoiese: applications cliniques. Revue Médicale de Liège, 62 (12), 725-9.

De Prijck, B., Baron, F., Beguin, Y., Bonnet, C., Willems, E., & Fillet, G. (2007). Actualités thérapeutiques en hématologie. Revue Médicale de Liège, 62 (5-6), 384-90.

Sorror, M. L., Sandmaier, B. M., Storer, B. E., Maris, M. B., Baron, F., Maloney, D. G., Scott, B. L., Deeg, H. J., Appelbaum, F. R., & Storb, R. (2007). Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. Journal of Clinical Oncology, 25 (27), 4246-54. doi:10.1200/JCO.2006.09.7865

Baron, F., Storer, B., Maris, M. B., Storek, J., Piette, F., Metcalf, M., White, K., Sandmaier, B. M., Maloney, D. G., Storb, R., & Boeckh, M. (November 2006). Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 12 (11), 1176-1187. doi:10.1016/j.bbmt.2006.07.004

Baron, F., & Sandmaier, B. M. (October 2006). Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia, 20 (10), 1690-1700. doi:10.1038/sj.leu.2404335

Baron, F., Storb, R., Storer, B. E., Maris, M. B., Niederwieser, D., Shizuru, J. A., Chauncey, T. R., Bruno, B., Forman, S. J., McSweeney, P. A., Maziarz, R. T., Pulsipher, M. A., Agura, E. D., Wade, J., Sorror, M., Maloney, D. G., & Sandmaier, B. M. (01 September 2006). Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. Journal of Clinical Oncology, 24 (25), 4150-4157. doi:10.1200/JCO.2006.06.9914

Baron, F., Sandmaier, B. M., Zellmer, E., Sorror, M., Storer, B., & Storb, R. (August 2006). Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after I Gy of total body irradiation. Biology of Blood and Marrow Transplantation, 12 (8), 813-817. doi:10.1016/j.bbmt.2006.05.001

Baron, F., & Storb, R. (2006). The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective. Best Practice and Research. Clinical Haematology, 19 (4), 637-53. doi:10.1016/j.beha.2006.06.002

Baron, F., & Storb, R. (January 2006). Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders [letter to the editor]. Molecular Therapy, 13 (1), 26-41. doi:10.1016/j.ymthe.2005.09.011

Baron, F., Vanstraelen, G., & Beguin, Y. (2006). Transfusions after nonmyeloablative or reduced-intensity conditioning regimens. Leukemia, 20 (12), 2081-6. doi:10.1038/sj.leu.2404431

Burroughs, L., Mielcarek, M., Leisenring, W., Sandmaier, B. M., Maloney, D. G., Baron, F., Martin, P., Flowers, M. E. D., Forman, S. J., Chauncey, T. R., Bruno, B., & Storb, R. (2006). Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation, 81 (6), 818-25. doi:10.1097/01.tp.0000203556.06145.5b

Castermans, E., Baron, F., Willems, E., Meuris, N., Schaaf-Lafontaine, N., Reynier, R., Geenen, V., & Beguin, Y. (2006). Immune reconstitution after CD8-depleted or unmanipulated peripheral blood stem cells transplantation with nonmyeloablative conditioning. Acta Clinica Belgica, 61 (2), 113.

Frere, P., Baron, F., Bonnet, C., Hafraoui, K., Pereira-Martins, M., Willems, E., Fillet, G., & Beguin, Y. (2006). Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplantation, 37 (4), 411-8. doi:10.1038/sj.bmt.1705255

Pirson, L., Baron, F., Gothot, A., & Beguin, Y. (2006). Impact of Imatinib on immune function in vitro [Poster presentation]. 21th general meeting of the Belgian Hematological Society, Brussels, Belgium.

Pirson, L.* , Baron, F.* , Meuris, N., Giet, O., Castermans, E., Greimers, R., Di Stefano, I., Gothot, A., & Beguin, Y. (2006). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice. Stem Cells, 24 (7), 1814-21. doi:10.1634/stemcells.2005-0290
* These authors have contributed equally to this work.

Vanstraelen, G., Baron, F., Willems, E., Bonnet, C., Hafraoui, K., Frere, P., Fillet, G., & Beguin, Y. (2006). Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response. Experimental Hematology, 34 (7), 841-50. doi:10.1016/j.exphem.2006.04.012

WILLEMS, E., CASTERMANS, E., Baron, F., BAUDOUX, E., Wanten, N., Bonnet, C., HAFRAOUI, K., Frère, P., Fillet, G., & Beguin, Y. (2006). Nonmyeloablative stem cell transplantation with CD8-depleted or unmalipulated peripheral blood stem cells: a prospective randomized trial [Paper presentation]. 21st General Meeting of the Belgian Hematological Society.

Baron, F., & Sandmaier, B. M. (November 2005). Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Current Opinion in Hematology, 12 (6), 435-443. doi:10.1097/01.moh.0000177830.63033.9d

Baron, F., Maris, M. B., Storer, B. E., Sandmaier, B. M., Panse, J. P., Chauncey, T. R., Sorror, M., Little, M. T., Maloney, D. G., Storb, R., & Heimfeld, S. (May 2005). High doses of transplanted CD34(+) cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia, 19 (5), 822-828. doi:10.1038/sj.leu.2403718

Baron, F., Maris, M. B., Storer, B. E., Sandmaier, B. M., Stuart, M. J., McSweeney, P. A., Radich, J. P., Pulsipbek, M. A., Agura, E. D., Chauncey, T. R., Maloney, D. G., Shizuru, J. A., & Storb, R. (April 2005). HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biology of Blood and Marrow Transplantation, 11 (4), 272-279. doi:10.1016/j.bbmt.2004.12.326

Baron, F., Maris, M. B., Sandmaier, B. M., Storer, B. E., Sorror, M., Diaconescu, R., Woolfrey, A. E., Chauncey, T. R., Flowers, M. E. D., Mielcarck, M., Maloney, D. G., & Storb, R. (20 March 2005). Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Journal of Clinical Oncology, 23 (9), 1993-2003. doi:10.1200/JCO.2005.08.136

Baron, F., Little, M.-T., & Storb, R. (2005). Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Reviews, 19 (3), 153-64. doi:10.1016/j.blre.2004.06.003

Baron, F., & Storb, R. (2005). Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning. Clinical Advances in Hematology and Oncology, 3 (10), 799-819.

Baron, F., Storb, R., Gooley, T., Sandmaier, B., Gisburne, S., Shin, S., Stroup, P., Baker, J., Maris, M., Maloney, D., Heimfeld, S., Grumet, F. C., Chauncey, T., Blume, K., & Little, M. T. (2005). Assessing donor chimerism level among CD3 T, CD4 T, CD8 T, and NK cells predicts subsequent graft rejection, GVHD, and relapse after allogeneic HCT with nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 11 (2), 11.

Diaconescu, R., Little, M.-T., Leisenring, W., Yunusov, M., Hogan, W. J., Sorror, M. L., Baron, F., & Storb, R. (2005). What role is there for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation? Biology of Blood and Marrow Transplantation, 11 (5), 335-44. doi:10.1016/j.bbmt.2005.01.001

Pirson, L., Baron, F., Meuris, N., Giet, O., Castermans, E., Greimers, R., Di Stefano, I., Gothot, A., & Beguin, Y. (2005). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDBeta2mNull [Poster presentation]. 20th general meeting of the Belgian Hematological Society, Brussels, Belgium.

Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005). Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106 (8), 2912-9. doi:10.1182/blood-2005-05-2004

Vanstraelen, G., Baron, F., Frere, P., Hafraoui, K., Fillet, G., & Beguin, Y. (2005). Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation. Haematologica, 90 (9), 1269-70.

Willems, E., Baron, F., Vanstraelen, G., Frere, P., Fillet, G., & Beguin, Y. (2005). Immunotherapie du cancer par minigreffe de cellules souches hematopoietiques. Revue Médicale Suisse, 1 (30), 1973-7.

WILLEMS, E., CASTERMANS, E., Baron, F., BAUDOUX, E., Wanten, N., Bonnet, C., HAFRAOUI, K., Frère, P., Fillet, G., & Beguin, Y. (2005). Nonmyeloablative stem cell transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a prospective randomized trial. Blood, 106 (1075).

Baron, F., Baker, J. E., Storb, R., Gooley, T. A., Sandmaier, B. M., Maris, M. B., Maloney, D. G., Heimfeld, S., Oparin, D., Zellmer, E., Radich, J. P., Grumet, F. C., Blume, K. G., Chauncey, T. R., & Little, M.-T. (2004). Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 104 (8), 2254-62. doi:10.1182/blood-2004-04-1506

Baron, F., Copizza, S., Baudoux, E., Jerusalem, G., Fillet, G., & Beguin, Y. (2004). CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer. Haematologica, 89 (9), 1146-8.

Baron, F., Maris, M., Sandmaier, B., Storer, B., Sorror, M., diaconescu, R., Woolfrey, A., Chauncey, T., Flowers, M., Mielcarek, M., Maloney, D., & Storb, R. (2004). Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Blood, 104.

Baron, F., & Storb, R. (2004). Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Seminars in Immunopathology, 26 (1-2), 71-94. doi:10.1007/s00281-004-0165-3

Pirson, L., Baron, F., Giet, O., Meuris, N., Bours, V., Fillet, G., Gothot, A., & Beguin, Y. (2004). The tyrosine kinase inhibitor Imatinib increases irradiation toxicity but does not impair engraftment of human CD34+ cells into NOD/SCIDB2mNull mice [Poster presentation]. 19th general meeting of the Belgian Hematological Society, Brussels, Belgium.

Baron, F., Baudoux, E., Frere, P., Tourqui, S., Schaaf-Lafontaine, N., Herens, C., De Prijck, B., Fillet, G., & Beguin, Y. (2003). Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC. Bone Marrow Transplantation, 32 (8), 829-34. doi:10.1038/sj.bmt.1704220

Baron, F., DRESSE, M.-F., & Beguin, Y. (2003). Transmission of chronic myeloid leukemia through peripheral-blood stem-cell transplantation. New England Journal of Medicine, 349 (9), 913-4. doi:10.1056/NEJM200308283490921

Baron, F., Frere, P., Baudoux, E., Sautois, B., Fillet, G., & Beguin, Y. (2003). Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma. Haematologica, 88 (4), 478-80.

Baron, F., Frere, P., Baudoux, E., Schaaf-Lafontaine, N., Fillet, G., & Beguin, Y. (2003). Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: an update. Haematologica, 88 (7), 835-7.

Baron, F., Frere, P., & Beguin, Y. (2003). Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment. Haematologica, 88 (6), 718-20.

Baron, F., Frere, P., Fillet, G., & Beguin, Y. (2003). Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. British Journal of Haematology, 123 (1), 103-5. doi:10.1046/j.1365-2141.2003.04556.x

Baron, F., Frere, P., Fillet, G., & Beguin, Y. (2003). Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Clinical Cancer Research, 9 (15), 5566-72.

Baron, F., Schaaf-Lafontaine, N., Humblet-Baron, S., Meuris, N., Castermans, E., Baudoux, E., Frere, P., Bours, V., Fillet, G., & Beguin, Y. (2003). T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Transplantation, 76 (12), 1705-13. doi:10.1097/01.TP.0000093987.11389.F7

Baron, F., Storb, R., & Little, M.-T. (2003). Hematopoietic cell transplantation: five decades of progress. Archives of Medical Research, 34 (6), 528-44. doi:10.1016/j.arcmed.2003.09.010

Beguin, Y., & Baron, F. (2003). Minitransplants: allogeneic stem cell transplantation with reduced toxicity. Acta Clinica Belgica, 58 (1), 37-45. doi:10.1179/acb.2003.58.1.005

Hafraoui, K., Humblet-Baron, S., Baron, F., Beguin, Y., & Fillet, G. (2003). Comment je traite ... la leucemie myeloide chronique (LMC). Revue Médicale de Liège, 58 (1), 7-12.

Herens, C., Baron, F., Croisiau, C., Tassin, F., & Bours, V. (2003). Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases. Cancer Genetics and Cytogenetics, 147 (1), 78-80. doi:10.1016/S0165-4608(03)00198-5

Humblet-Baron, S., Baron, F., Chachati, A., Bury, J., Morelon, E., Kreis, H., & BEGUIN, Y. (2003). Donor lymphocyte infusion for late relapse followed by kidney transplantation for end-stage renal failure after allogeneic bone marrow transplantation for chronic myeloid leukemia. Transplantation, 76 (10), 1531-2. doi:10.1097/01.TP.0000085285.59061.D7

Pirson, L., Baron, F., Giet, O., Meuris, N., Bours, V., Fillet, G., Gothot, A., & Beguin, Y. (2003). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor STI571 does not impair engraftment of human CD34+ cells into NOD/SCIDB2mNull mice [Poster presentation]. 32nd annual meeting of the International Society of Experimental Hematology, Paris, France.

Pirson, L., Baron, F., Giet, O., Meuris, N., Bours, V., Fillet, G., Gothot, A., & Beguin, Y. (2003). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor STI571 does not impair engraftment of human CD34+ cells into NOD/SCIDB2mNull mice [Poster presentation]. 18th general meeting of the Belgian Hematological Society, Brussels, Belgium.

Humblet-Baron, S., Baron, F., Pirson, L., Beguin, Y., & Fillet, G. (28 August 2002). Traitement moléculaire du cancer: le STI571, un inhibiteur des tyrosines kinases. Revue Médicale Suisse, 60 (598), 1504-1508.

Baron, F., Baudoux, E., Fillet, G., & Beguin, Y. (2002). Retrospective comparison of CD34-selected allogeneic peripheral blood stem cell transplantation followed by CD8-depleted donor lymphocyte infusions with unmanipulated bone marrow transplantation. Hematology, 7 (3), 137-43. doi:10.1080/1024533021000008173

Baron, F., Baudoux, E., Frere, P., Tourqui, S., Schaaf-Lafontaine, N., Greimers, R., Herens, C., Fillet, G., & Beguin, Y. (2002). Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells. Journal of Hematotherapy and Stem Cell Research, 11 (2), 301-14. doi:10.1089/152581602753658484

Baron, F., & Beguin, Y. (2002). Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 8 (7), 351-9. doi:10.1053/bbmt.2002.v8.pm12171481

Baron, F., & Beguin, Y. (2002). Nonmyeloablative allogeneic hematopoietic stem cell transplantation. Journal of Hematotherapy and Stem Cell Research, 11 (2), 243-63. doi:10.1089/152581602753658448

Baron, F., Fillet, G., & Beguin, Y. (2002). Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation. Transplantation, 74 (12), 1692-6. doi:10.1097/00007890-200212270-00008

Baron, F., Frere, P., Herens, C., Fillet, G., & Beguin, Y. (2002). Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML. Haematologica, 87 (12), 43.

Baron, F., Sautois, B., Baudoux, E., Matus, G., Fillet, G., & Beguin, Y. (2002). Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 30 (6), 546-54. doi:10.1016/S0301-472X(02)00795-6

Baron, F., Siquet, J., Schaaf-Lafontaine, N., Baudoux, E., Hermanne, J.-P., Fillet, G., & Beguin, Y. (2002). Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation. Haematologica, 87 (1), 78-88.

Baron, F., Turhan, A. G., Giron-Michel, J., Azzarone, B., Bentires-Alj, M., Bours, V., Bourhis, J. H., Chouaib, S., & Caignard, A. (2002). Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood, 99 (6), 2107-13. doi:10.1182/blood.V99.6.2107

Pirson, L., Baron, F., Giet, O., Meuris, N., Bours, V., Fillet, G., Gothot, A., & Beguin, Y. (2002). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibior STI571 does not impair engraftment of human CD34+ cells into NOD/SCIDB2mNull mice [Poster presentation]. 44th annual meeting and exposition of American Society of Hematology, Philadelphia, United States.

Baron, F. (2001). Immunothérapie après greffe de cellules souches hématopoïétiques [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/102195

Baron, F., Frere, P., Fillet, G., & Beguin, Y. (2001). Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571. Haematologica, 86 (9), 993-4.

Baron, F., & Beguin, Y. (2000). Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion, 40 (4), 468-76. doi:10.1046/j.1537-2995.2000.40040468.x

Baron, F., Dresse, M.-F., & Beguin, Y. (2000). Donor lymphocyte infusion to eradicate recurrent host hematopoiesis after allogeneic BMT for sickle cell disease. Transfusion, 40 (9), 1071-3. doi:10.1046/j.1537-2995.2000.40091071.x

Baron, F., Gothot, A., Salmon, J., Hermanne, J. P., Pierard, G., Fillet, G., & Beguin, Y. (2000). Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. British Journal of Haematology, 111 (3), 745-53. doi:10.1046/j.1365-2141.2000.02470.x

Baron, F., Ribbens, C., Kaye, O., Fillet, G., Malaise, M., & Beguin, Y. (2000). Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation. British Journal of Haematology, 110 (2), 339-342. doi:10.1046/j.1365-2141.2000.02191.x

Baron, F., Hermanne, J.-P., Dowlati, A., Weber, T., Thiry, A., Fassotte, M.-F., Fillet, G., & Beguin, Y. (1998). Bronchiolitis obliterans organizing pneumonia and ulcerative colitis after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 21 (9), 951-4. doi:10.1038/sj.bmt.1701198

Baron, F., Hermanne, J. P., Fassotte, M.-F., Beguin, Y., & Fillet, G. (1998). Le cas clinique du mois. Association d'une maladie de Hodgkin et d'un syndrome nephrotique. Revue Médicale de Liège, 53 (11), 651-3.

Baron, F., Sadzot, B., Wang, F.-C., & Beguin, Y. (1998). Myasthenia gravis without chronic GVHD after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 22 (2), 197-200. doi:10.1038/sj.bmt.1701297

Beguin, Y., Baron, F., & Fillet, G. (1998). Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. Haematologica, 83 (12), 1076-81.

Daniel, C., Baron, F., & Moutschen, M. (1998). Le cas clinique du mois. A propos d'une pancytopenie chez un patient seropositif. Revue Médicale de Liège, 53 (12), 732-4.

Baron, F., & Beguin, Y. (1997). Complications hépatiques de la chimiothérapie : de la cytolyse banale à la maladie veino-occlusive du foie. Médecine and Chirurgie Digestives, 26, 269-272.

Baron, F., & Beguin, Y. (1997). Complications hepatiques de la chimiotherapie. De la cytolyse banale a la maladie veino-occlusive du foie. Revue Médicale de Liège, 52 (2), 93-7.

Baron, F., Deprez, M., & Beguin, Y. (1997). The veno-occlusive disease of the liver. Haematologica, 82 (6), 718-25.

BARON, F., SADZOT, B., WANG, F.-C., & BEGUIN, Y. (1997). Myasthenia gravis without chronic GVHD after allogenic bone marrow transplantation [Paper presentation]. 23rd Annual Meeting European group for Blood and Marrow Transplantation and 13th Meeting of the Nurses group.

Patel, N., Alsat, E., Igout, A., Baron, F., Hennen, G., Porquet, D., & Evain-Brion, D. (1995). Glucose inhibits human placental GH secretion, in vitro. Journal of Clinical Endocrinology and Metabolism, 80 (5), 1743-6. doi:10.1210/jcem.80.5.7745029